division researcher type sponsor 2007 title ......samples from clinical trial protocols a4001027,...

UBC Department of Medicine Annual Report 2007

DIVISION RESEARCHER TYPE SPONSOR 2007 FUNDING

TITLE

AIDS Harrigan Agreement Pfizer Ltd (UK)

206,710 Samples from Clinical Trial Protocols A4001027, A4001028, and A4001029 of Compound UK-427,857

AIDS Harrigan Clinical Trial Pfizer Canada Inc. 1,050,000

HIV Co-receptor Usage Assay by Quantitative Population...

AIDS Harrigan Grant Abbott Laboratories Ltd. (Canada) 327,478

Abbott/BC-CfE Research Support and Collaboration Agreement

AIDS Kerr Grant CIHR Operating Grant MOP-81171 54,700

Exploring the natural history of injection drug use: A qualitative study of social and environmental influences

AIDS Kerr Grant MSFHR Scholar Award CI-SCH-085(05-1) HSR

45,000

An investigation of injection drug use and HIV infection among drug using youth

AIDS Kerr Grant MSFHR Establishment Grant CI-SCH-085(05-1)

75,000

An investigation of injection drug use and HIV infection among drug using youth

AIDS Kerr Grant CIHR: HIV/AIDS Research Program CBR-79873

90,973

Evaluating a peer-driven safer injecting education program

AIDS Kerr Grant MSFHR Matching Establishment Grant CI-SCH-085(05-1)

50,000

An investigation of injection drug use and HIV infection among drug-using youth

AIDS Kerr Grant CIHR New Investigator MSH-80536 58,500

An investigation of injection drug use and HIV infection among drug-using youth

AIDS Kerr Grant CIHR Operating Grant RAA-79918 167,568

Vancouver multi-disciplinary collaboration of injection drug use researchers

AIDS Montaner Clinical Trial Abbott Laboratories Ltd. (Canada) 2,120

Protocol M06-802 (version 1.0): A Phase 3, Randomized, Open Label Study of Lopinavir/Ritonavir Tablets 800/200mg Once-Daily Versus 400/100mg Twice-Daily When Co-administered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Ant

AIDS Montaner Grant CIHR Fellowship (HIV/AIDS) - Health Services/Population Health Stream ZNF-84404 (Fellow: Lima, Viviane Dias)

5,000

Research Allowance: Longitudinal impact of adherence on HIV/AIDS disease progression: implications for interventions

AIDS Montaner Grant CIHR Fellowship (HIV/AIDS) - Health Services/Population Health Stream ZNF-84404 (Fellow: Lima, Viviane Dias)

33,333

Salary: Longitudinal impact of adherence on HIV/AIDS disease progression: implications for interventions

AIDS Montaner Clinical Trial Merck Frosst Canada Ltd. 3,000

Protocol 023-00 (MK-0518 Early Access): Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options


AIDS Montaner Grant Abbott Laboratories Ltd. (Canada) 52,670

A06-320

AIDS Montaner Clinical Trial TheraTechnologies Inc. 8,000

Protocol TH9507-CTR-1011: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2mg Dose of TH9507, A Growth Hormone Releasing Factor Analog, in HIV Subjects With Excess Abdominal Fat…

AIDS Montaner Clinical Trial University of New South Wales 10,000

Protocol Altair: A Randomised Open-Label Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection

AIDS Montaner Clinical Trial Tibotec Pharmaceuticals Ltd. 33,600

Protocol TMC125-C214 (EAP) Version 1.1: Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment Experienced HIV-1 Infected Subjects With Limited Treatment Options

AIDS Montaner Grant Janssen-Ortho Inc. 10,000

Fellowship for Dr. Mark Hull: Dual-boosted protease inhibitors

AIDS Montaner Grant Janssen-Ortho Inc. 100,000

Grant BC CFE

AIDS Montaner Clinical Trial GlaxoSmithKline (Canada) Inc. 62,360

IICT: Study Evaluating the Frequency and Factors Associated with Osteoporosis in the HAART Era

AIDS Montaner Clinical Trial Merck and Co. Inc. 5,894

Protocol 0518-019 - A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Thera

AIDS Montaner Clinical Trial Abbott Laboratories Ltd. (Canada) 71,881

IICT: Evaluating treatment options in dyslipidemic HIV+ patients on PI-based HAART: Population-based Analysis

AIDS Montaner Clinical Trial Tibotec Pharmaceuticals Ltd. 4,203

(TMC125-C216) A Phase III Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as part of an ART Including TMC114/RTV and an Investigator-selected OBR Regimen in HIV-1 Infected Patients…

AIDS Montaner Clinical Trial Pfizer Canada Inc. 12,930

(A4001027) A Multicenter, Randomized, Double-blind, Placebo- controlled Trial of a Novel CCR5 Antagonist, UK-427,857, n Combination with Optimized Background Therapy vs. Optimized Background Therapy Alone for the Treatment of Antiretroviral…

AIDS Wood Grant National Institutes of Health - Research Grant

463,866

Impacts of Universal Access to HIV/AIDS Care Among HIV+ Injection Drug Users

AIDS Wood Grant National Institutes of Health - Research Grant

504,207

Evaluating the natural history of injection drug use


AIDS Wood Grant CIHR Operating Grant HHP-67262 155,189

Investigating and addressing barriers to human immunodeficiency virus (HCV) and Hepatitis C Virus (HCV) care among injection drug users

AIDS Wood Grant CIHR: Postdoctoral Fellowship HPF-81715 (Fellow: Stoltz, Jo-Anne)

40,000

Salary: An investigation of the impact of trauma and crystal methamphetamine use on injection drug use and HIV infection among drug-using youth

AIDS Wood Grant CIHR: Postdoctoral Fellowship HPF-81715 (Fellow: Stoltz, Jo-Anne)

5,000

Research Allowance: An investigation of the impact of trauma and crystal methamphetamine use on injection drug use and HIV infection among drug-using youth

AIDS Wood Grant CIHR Operating Grant HHP-67262 158,355

The Vancouver injection drug user's study: A programme of study of HIV and Hepatitis C and other harms related to injection drug use

Allergy & Immunology

Kanani Grant Bayer HealthCare Biological Products Division

123,025

A Pilot Study of Quality of Life, Mood, Sleepiness, and Fatigue in Patients With Primary Immune Deficiency Receiving Intravenous Immunoglobulin (IVIG)


Stark Clinical Trial Talecris Biotherapeutics Inc. 26,758

Protocol 060001 (Talecris SC-IG): An Open-Label Single-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous Gamunex(R) 10% in Subjects with Primary Immunodeficiency (PID)


Schellenberg Grant Various Sources 20,000

Various sources

Cardiology Aymong Clinical Trial The Medicines Co.

10,325 The ACUITY Trial: A randomized comparison of Angiomas (bivalirudin) vs. Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation

Cardiology Aymong Clinical Trial National Institutes of Health 20,425

IICT: Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM Trial)

Cardiology Aymong Grant Vancouver Coastal Health Authority 6,410

A double blind, randomized trial of abbreviated versus prolonged infusion of eptifibatide following successful coronary stenting (a.k.a. BRIEF)

Cardiology Aymong Clinical Trial AstraZeneca Canada Inc. 4,240

Comparison of the Effects Noted in the ApoB/ApoA-I Ration Using Rosuvastatin and Atorvastin in Patients with Acute Coronary Syndrome - CENTAURUS

Cardiology Aymong Clinical Trial Schering-Plough International 300

EARLY ACS: Early Glycoprotein IIb/IIIa Inginitionin Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with...


Cardiology Aymong Clinical Trial Eli Lilly and Co. 705

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention/TIMI-38

Cardiology Bernstein Clinical Trial Servier Canada 12,736

CL3-16257-056: Effects of Ivabradine on Cardiovascular Events in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-Year Randomised Double-Blind Placebo-Controlled International Multicentre Sty

Cardiology Bernstein Grant Various Pharmaceutical Companies 96,000

Cardiology Research

Cardiology Bernstein Agreement Sanofi-Aventis 3,439

AUDITOR STUDY - Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20mg, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-Media Thickness, in overweight patients…

Cardiology Bernstein Clinical Trial Hamilton Health Sciences Corporation

8,560

ONTARGET: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

Cardiology Bernstein Agreement Sanofi-Aventis 15,695

RIMONR00961: A Pan-European Randomized, Parallel Group, Two-arm, Placebo-controlled, Double-blind, Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients with Impaired Fasting Blood Glucose with or without…

Cardiology Bernstein Clinical Trial National Institutes of Health 6,882

IICT: STICH 6400: Surgical Treatment for Ischemic Heart Failure

Cardiology Bernstein Clinical Trial Canadian Institutes of Health Research

600

AF-CHF: Atrial Fibrillation and Congestive Heart Failure

Cardiology Buller Clinical Trial National Institutes of Health 2,486

IICT: Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)

Cardiology Buller Agreement Abbott Vascular Devices 3,270

Zomaxx II Study: A Randomized Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx drug Eluting Coronary Stent System as compared to the Taxus Express Paclitaxel-Eluting Stent in de-novo Coronary Artery Lesions

Cardiology Buller Agreement Schering-Plough Research Institute 36,522

TRANSCENDENCE-PCI: A Multicentre, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of SCH530348 in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention

Cardiology Buller Clinical Trial Cordis Corp. 128,412

1525004 ACROSS-Cypher: Approaches to Chronic Occlusions with Sirolimus Stents-Cypher - Total Occlusion Study of Coronary Arteries 4

Cardiology Buller Agreement Edwards Life sciences LLC 53,201

EVOLUTION - Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the treatment of Mitral Regurgitation


Cardiology Buller Clinical Trial Boston Scientific Corp. 2,500

TAXUS ATLAS: Multicenter Single-Arm Study of the TAXUS Liberte-SR Stent for the Treatment of Patients with De Novo Coronary Artery Lesions

Cardiology Buller Clinical Trial Takeda Global Research and Development

23,258

01-01-TL-OPI-516 - PERISCOPE: Double-Blind Randomized Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCL vs Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease…

Cardiology Carere Grant St Lukes-Roosevelt Institute For Health Sciences

6,595

Open Artery Trial (OAT II)

Cardiology Carere Agreement Medical Research Council of Canada 9,450

Clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) Trial

Cardiology Chan Clinical Trial Sanofi-Aventis 48,296

Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD For Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors

Cardiology Fung Clinical Trial The Medicines Co. 17,039

TMC-BIV-02-08 Acuity: Randomized Comparison of Angiomax (bivalirudin) vs Lovenox/Clexane (enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndrome Without ST-segment Elevation

Cardiology Fung Agreement Sanofi Recherche 31,900

EFC 5965: Randomized, Multinational, Double-Blind Study, comparing a High Loading Dose Regimen of Clopidogrel versus Standard Dose in Patients with Unstable Angina or Non-ST Segment Elevation Myocardial Infarction Managed with an Early Int

Cardiology Fung Clinical Trial CV Therapeutics Inc. 10,056

CVT 5131: Phase III Randomized Double-Blind Study of Intravenous CVT-3146 vs Adensocan in Patients Undergoing Stress Myocardial Perfusion Imaging

Cardiology Fung Grant VCHA 621,594

Interventional cardiology research - clinical research coordinators positions

Cardiology Fung Clinical Trial National Institutes of Health 101,330

IICT: Atherothrombbosis Intervention in Metabolic Syndrome with Low HDL High Triglycerides & Impact on Global Health Issues (AIM-HIGH)

Cardiology Gin Clinical Trial Sanofi-Aventis Canada Inc. 2,850

Protocol EFC4912 (ACTIVE): Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events

Cardiology Gin Clinical Trial Atherogenics Inc. 25,086

AGI-1067-042 ARISE: Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Study the Reduction of Vascular Inflammation & Coronary Atherosclerosis with AGI-1067, a V-Protectant Reduces Cardiovascular Events in Patients with Coronary...

Cardiology Gin Agreement Atherogenics Inc. 36,896

Follow up of Clinical Outcomes: The Long-Term AGI-1067 plus Usual Care Study- FOCUS


Cardiology Gin Agreement Sanofi-Aventis 106,077

EFC-5826: Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm, Parallel-group Trial of Rimonabant 20mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering Riso…

Cardiology Hamburger Agreement Angiometrx Inc. 13,500

"GAAME"- Gemini Angioplasty & Arterial Measurement Evaluation - An evaluation of the Metricath Gemini System, a percutaneous interventional device intended to make arterial lumen measurements and perform percutaneous transluminal angioplasty…

Cardiology Humphries Grant MSFHR Career Investigator Program 20,000

Secondary prevention - the gap between evidence and practice

Cardiology Humphries Grant CIHR New Investigator MSH-80517 58,500

Angina with "normal" coronary arteries: sex differences in presentation and outcome

Cardiology Humphries Grant CIHR Operating Grant 143,705

Angina with "normal" coronary arteries: sex differences in presentation and outcome

Cardiology Ignaszewski Clinical Trial Novartis Pharmaceuticals Canada Inc.

247

A three-month, multicenter, open-label, single arm, pilot study of the renal safety of everolimus in addition to Neoral in cardiac transplant recipients

Cardiology Ignaszewski Clinical Trial Pfizer Inc. 35,827

A Phase III, multi-center, double-blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily(QD) compared with atorvastatin alone on the occurrence of major cardiovascular events in…

Cardiology Jue Contract Various Sources 9,803

Echo Research Account

Cardiology Jue Grant Canadian Institutes of Health Research

2,040

Protocol DC-452-003: ASTRONOMER - The Effect of Cholesterol Lowering on Progression of Aortic Stenosis in Patients with Mild to Moderate Aortic Stenosis

Cardiology Jue Clinical Trial Guidant Corp. 7,300

CAFI: Canadian Atrial Fibrillation Evaluation Study

Cardiology Kerr Grant Canadian Institutes of Health Research

104,861

Resynchronization/Defibrillation for Advanced Heart Failure

Cardiology Kerr Clinical Trial Guidant Corporation 1,500

Canadian Registry of ICD Implant Testing Procedures

Cardiology Kerr Grant Sanofi-Aventis Canada Inc. 82,000

Data Analysis: CARAF II and CAFAF II Databasics

Cardiology Mancini Grant Various Sources 32,300

Quantitative Vascular Studies

Cardiology Mancini Contract Cordis Corp. 72,827

SA: Approaches to Chronic Occlusions with Sirolimus Stents-Cypher (ACROSS-CYPHER)


Cardiology Moss Clinical Trial Novartis Pharmaceuticals Canada Inc.

10,000

A 24-month, mulicentre, randomized, open-label, non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral 3.0 gMMF with standard dose Neoral in de Novo Heart transplant

Cardiology Ramanathan Agreement AstraZeneca Canada Inc. 18,525

PLATO (D5130C05262): A Randomized, Double-blind, Parallel-group, Phase III Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndrome (ACS)

Cardiology Ramanathan Grant Sanofi-Aventis Canada Inc. 3,000

Protocol GRACE 2: The Global Registry of Acute Coronary Events Expanded Enrollment Program

Cardiology Ricci Clinical Trial National Institutes of Health 62,718

IICT: FREEDOM: Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease

Cardiology Ricci Clinical Trial Eli Lilly Canada Inc. 40,707

H7T-MC-TAAL (TIMI 38): A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention / TIMI 38

Cardiology Saw Agreement The Medicines Co. 3,000

TMC-CAN-0502: A Clinical Trial Comparing Cangrelor to Cloipidogrel in Subjects who Require Percutaneous Coronary Intervention

Cardiology Saw Agreement The Medicines Co. 17,000

TMC-CAN-05-03: A Clinical Trial Comparing Treatment with Cangrelor (in combination with usual care) in Subjects who Require Percutaneous Coronary Intervention CHAMPION PLATFORM

Cardiology Tung Clinical Trial Medtronic USA 2,145

SAVE PACe - Search AV Extension for Promoting Atrioventricular Conduction

Cardiology Webb Clinical Trial Boston Scientific Corp. 500

SYMBIOT III: A prospective randomized trial evaluating the Symbiot III covered stent system in saphenous vein grafts

Cardiology Webb Clinical Trial Angiometrx Inc. 8,100

Protocol GAAME: Gemini Angioplasty and Arterial Measurement Evaluation

Cardiology Webb Clinical Trial Hoffmann-La Roche Ltd. (Canada) 4,318

WEST: Which Early ST Elevation Myocardial Infarction Therapy?

Cardiology Webb Clinical Trial Edwards Lifesciences LLC 16,258

REVIVE Trial - Registry of EndoVascular Implantation of Valves in Europe

Cardiology Webb Clinical Trial TherOx Inc. 11,126

AMI HOT II - A Prospective, Multicentered, Randomized Study of Aqueous Oxygen Therapy for 90 Minutes in Anterior Acute Myocardial Infarction Patients with Successful PCI/Stenting Presenting Within </= Six Hours From Time of Symptom Onset



Milano II Feasibility Study


TVI Registry: Transcatheter Valve Implantation Vancouver Experience


Evolution: Edwards LifeScience Percutaneous Mitral Annulopasty Repair System: A Phase I Feasibility, Non-randomized, Multicenter, Prospective, Consecutive Registry -- A Percutaneous Interventional Treatment of Mitral Regurgitation

Cardiology Webb Clinical Trial Sanofi-Synthelabo 5,000

SHINE TRIAL: A randomized dose ranging study of Hexadecasaccharide including active control, in patients with unstable angina or non-ST-segment elevation myocardial infarction scheduled to undergo percutaneous coronary intervention

Cardiology Webb Clinical Trial Boston Scientific Corp. 238

TAXUS II: A double-blind, controlled, study of the safety and performance of the NIRx(TM) Paclitaxel-coated conformer coronary stent

Cardiology Wong Agreement Schering-Plough Research Institute 15,177

IMPROVE-IT

Cardiology Wong Grant Vancouver Coastal Health Authority 50,000

A Four-year Evaluation of Door-to-Balloon Time and Factors associated with Door-to-Balloon time Prolongation for Primary Percutaneous Coronary Intervention

Cardiology Wong Agreement AstraZeneca Canada Inc. 89,415

D356OL00052 Comparison of the Effects noted in the ApoB/Apo-A-I ratio Using Rosuvastatin and Atorvastatin in patients with acUte coronary Syndrome - CENTAURUS

Cardiology Wong Agreement Sanofi-Aventis Canada Inc. 8,268

IICT: Global registry of Acute Coronary Events Expanded Enrollment Program, Centre for Outcomes Research, University of Massachusetts Medical School (GRACE2)

Critical Care Chittock Grant CIHR Randomized Controlled Trials

MCT-80244 in collaboration with the Institute of Nutrition, Metabolism and Diabetes

1,162,943

(SUGAR) Survival Using Glucose Algorithm Regulation

Critical Care Chittock Agreement Takeda Global Research and Development

5,476

TAK-242-011 A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TAK 242 in Adults with Severe Sepsis

Critical Care Chittock Clinical Trial CIHR Randomized Controlled Trials in collaboration with McMaster University

21,128

IICT: Prophylaxis for Thromboembolism in Critical Care Trial (PROTECT Study)

Critical Care Chittock Agreement Eisai Inc. 25,759

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis


Critical Care Chittock Clinical Trial Novartis Pharmaceuticals Canada Inc.

11,883

Protocol TFP008: Phase III Multicenter, Randomized, Placebo-controlled Double-blind, Three-arm Study to Evaluate the Safety & Efficacy of Tifacogin (recombinant tissue factor pathway inhibitor) Administration in Subjects with Severe Community...

Critical Care Chittock Clinical Trial Fresenius Kabi Deutschland GmbH in collaboration with CIHR and Kingston General Hospital Clinical Evaluation Research

1,500

IICT - A randomized trial of glutamine and antioxidant supplementation in critically ill patients: The REDOXS Study

Critical Care Chittock Agreement Various Sources 159,619

Various Clinical Trials Agreements

Critical Care Dodek Grant CIHR Strategic/ RFA Knowledge Translation-Research Syntheses KRS-82618

52,663

Scoping and systematic review of non-invasive mechanical ventilation: Laying the groundwork for development of clinical practice guidelines

Critical Care Dodek Agreement CIHR Team Grant PET-69818 in collaboration with Dalhousie University, Queen's University and Royal Alexandra Hospital

37,976

Understanding and improving communication and decision-making at the end of life

Critical Care Dodek Grant MSFHR HSPR Operating Grants Program - LOI

74,860

HSPRSN Investigative Teams development grant - Intensive Care Unit Patient Safety Team

Critical Care Dodek Grant CIHR Operating Grant 5,500

Active observational study of the adoption and transfer of clinical practice guidelines through education, for ventilator associated pneumonia - ABATE VAP Study

Critical Care Dodek Grant CIHR: Partnership for Health System Improvement PHE-78693

64,726

Relationship between organizational culture and family satisfaction in critical care

Critical Care Dorscheid Grant British Columbia Lung Association 22,500

EGF-receptor glycosylation and airway epithelial repair in asthma…

Critical Care Dorscheid Grant CIHR Doctoral Research Award Fellowship (Fellow: Patchell, Benjamin)

4,583

The role and characterization of Annexin II in airway epithelial wound repair in normal and asthmatic epithelium

Critical Care Dorscheid Grant CIHR Fellowship (Fellow: MacRedmond, Ruth)

5,000

Research Allowance: Acute Lung Injury: FasL, Apoptosis and Protection by Erythropoietin

Critical Care Dorscheid Grant MSFHR Fellowship (Fellow: MacRedmond, Ruth)

50,000

Salary: Acute Lung Injury: FasL, Apoptosis and Protection by Erythropoietin

Critical Care Dorscheid Grant CIHR Operating Grant 100,000

Conjugated Linoleic Acid and Airway Health in Asthma

Critical Care Dorscheid Grant British Columbia Lung Association 21,000

Airway Inflammation and CLA to Reduce Airway Remodeling

Critical Care Dorscheid Grant CIHR Postdoctoral Trainee Fellowship (Fellow: MacRedmond, Ruth)

7,000

Acute lung injury: FasL, Apoptosis and protection by Erythropietin


Critical Care Dorscheid Grant MSFHR Scholar Award 45,000

Airway epithelial injury as a result of corticosteroid-induced apoptosis

Critical Care Dorscheid Grant Canadian Institutes of Health Research (CIHR)

58,500

Glycomics of airway epithelial repair

Critical Care Russell Grant CIHR Doctoral Research Award Fellowship (Fellow: Sutherland, Ainsley)

1,000

Genetic determinants of the host response to infection in critically ill adults with systemic inflammatory response syndrome

Critical Care Russell Clinical Trial Chiron Corp. 65,600

A phase III, multicentre, randomized, placebo-controlled, double-blind, three-arm study to evaluate the safety and efficacy of Tifacogin (recombinant tissue factor pathway inhibitor) administration in subjects with severe community-acquired pneumonia…

Critical Care Russell Contract Medical Research Council of Canada 4,850

A randomized trial of a lung open ventilation strategy in acute lung injury

Critical Care Walley Grant CIHR Operating Grant 122,899

Toll-like receptor signaling in cardiac inflammatory states

Critical Care Walley Grant MSFHR: Distinguished Scholar Award CI-DSH-73(02-1)

120,000

Translating mechanistic understanding of the systemic inflammatory response syndrome (SIRS) to clinical practice via genomics

Critical Care Walley Grant CIHR Operating Grant 40,476

Influence of polymorphisms in coagulation pathway in inflammatory mediator genes on phenotype post-cardiopulmonary bypass surgery

Critical Care Walley Grant MSFHR Postdoctoral Trainee Fellowship ST-PEF-154(06-1) CLIN (Fellow: Boyd, John)

39,000

The heart as an immunologic organ: cardiac myocytes in innate immunity

Critical Care Walley Contract Sirius Genomics Inc. 484,026

CRA: Association of the influence of inflammatory mediator polymorphisms with outcomes in systemic inflammatory response syndrome (SIRS) and multiple organ system failure (MOSF); and SNP Discovery using a whole Genome scan linkage analysis

Endocrinology Elliott Agreement Hoffmann-La Roche Ltd. (Canada)

874 BM18249 - A Multicenter, Double-blind, Randomized, Placebo-controlled Dose Ranging, Phase II Study to Investigate Efficacy Safety, Tolerability and Pharmacokinetics of RO4389620 in patients with Type-2 Diabetes Mellitus Treated with a Stabfn

Endocrinology Elliott Clinical Trial Amgen Inc. 21,429

TREAT - 20010184: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin alfa) Therapy

Endocrinology Elliott Agreement Hoffmann-La Roche Ltd. (Canada) 15,106

Protocol: NC19794 - A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in Type-2 Diabetic patients from studies BM18248 and BM18249


Endocrinology Elliott Clinical Trial Novartis Pharmaceuticals Canada Inc.

16,969

CDJN608B2302: Navigator Randomized, Double-blind, Placebo-controlled, Forced-titration 2x2 Factorial Design Study of the Efficacy & Safety of Long-term Administration of Nateglinide & Valsartan in the Prevention of Diabetes & Cardiovascular Disease

Endocrinology Elliott Clinical Trial National Institutes of Health 400,901

IICT ACCORD Eye Study: A Substudy of the Action to Control Cardiovascular Disease in Diabetes Study

Endocrinology Kreisman Agreement National Institutes of Health 321

Diabetes Therapy to Improve BMI and Pulmonary Function in CF Subjects with Abnormal Glucose Tolerance

Endocrinology Prior Grant Donations for Health Science Research

212,714

(CEMCOR) Centre for Menstrual Cycle and Ovulation Research

Endocrinology Prior Grant CIHR/ Rx&D Research Program 166,610

(CAMOS) Canadian Multicentre Osteoporosis Study: A cross-sectional and prospective observational study of bone density, bone strength and fracture risk

Endocrinology Sirrs Clinical Trial University Health Network in collaboration with the BC Ministry of Health

123,438

Enzyme Replacement Therapy for Fabry Disease: A Model for the Integration of Rare Disease Therapeutics into the Canadian Health Care System

Endocrinology Thompson Clinical Trial Novo-Nordisk 8,425

A randomised, parallel-group, open-label, multinational trial comparing the efficacy and safety of insulin determir (Levemir R) vs. human insulin (Insulin NPH) used in combination with insulin… with type-1 diabetes

Endocrinology Thompson Grant Canadian Institutes of Health Research (CIHR)

10,000

To reduce IDDM in Type-1 diabetes in the genetically at risk TRIGR

Gastroenterology Anderson Clinical Trial Bristol-Myers Squibb Co. (Canada)

2,067 Protocol AI463049: Long-term Assessment of Treatment Outcomes with Entecavir & Lamivudine for Chronic Hepatitis B Infection in Patients Who Have Enrolled in Phase III Entecavir Trials

Gastroenterology Anderson Clinical Trial Schering Canada Inc. 3,335

Protocol P02569: PEG-Intron as Maintenance Therapy vs an Untreated Control Group in Adult Subjects with Compensated Cirrhosis (METAVIR F4) Secondary to Chronic Hep C who have Failed to Respond to Therapy with Any alpha Interferon + Ribaviri

Gastroenterology Anderson Clinical Trial Schering Canada Inc. 2,091

Protocol P02570: PEG-Intron as Maintenance Therapy vs an Untreated Control Group for Prevention of Fibrosis in Adult Subjects with Chronic Hep C with Hepatic Fibrosis (METAVIR fibrosis score of F2/F3) Who Have Failed Therapy with PEG-Intron

Gastroenterology Anderson Clinical Trial Centocor Inc. 2,242

Protocol C0168T37 (ACT 1): Randomized Placebo-Controlled Double-Blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with Active Ulcerative Colitis


Gastroenterology Anderson Clinical Trial Bristol-Myers Squibb Pharmaceutical Group (Canada)

13,385

Protocol AI463-901: A Preliminary Assessment of Safety and Antiviral Activity of Open-Label Entecavir Plus Lamivudine Therapy in Subjects with Chronic Hepatitis B Who Have Viremia on Monotherapy in Other Entecavir Trials

Gastroenterology Anderson Clinical Trial Tillotts Pharma AG 4,343

Protocol TP0308: - EPIC-2 Phase III Randomized Placebo-Controlled Double-Blind Parallel Group Multicentre Study to Assess the Efficacy & Safety of Omega-3 Free fatty Acids (Epanova) for the Maintenance of Symptomatic Remission in Subjects…

Gastroenterology Enns Clinical Trial Otsuka America Pharmaceutical Inc. 25,538

A Prospective, Open-Label Study to Evaluate the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease (512-04-208)


A Prospective, Randomized, Double-blinded, Placebo (Sham)-controlled Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease (512-04-206)


512-04-207: A Prospective, open-label study to evaluate the Adacolumn Aspheresis System for the treatment of moderate to severe Ulcerative Colitis

Gastroenterology Enns Clinical Trial Abbott Laboratories 80,454

A Multicenter, Open-label Study of the Human Anti-TNF Monoclonal Adalimumab in Subjects with Crohn's Disease (M04-690)

Gastroenterology Enns Grant University of Alberta 5,512

A randomized, placebo-controlled, double-blind, multicenter, study to determine the efficacy and safety of VSL #3 probiotic food supplement mixture in prevention of endoscopic recurrence of Crohn's disease after ileo-colonic surgical resect

Gastroenterology Enns Clinical Trial Tillotts Pharma AG 2,625

A phase III randomized, placebo-controlled, double-blind, parallel group, multi-centre study to assess the efficacy and safety of Omega-3 free fatty acids (Epanova(TM)) for the maintenance of symptomatic remission in subjects with Crohn's Disease

Gastroenterology Enns Clinical Trial Abbott Laboratories 9,115

M02-433 A multi-center, randomised, double-blind, placebo-controlled study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of clinical remission in subjects with Crohn's disease. Clinical Study Protocol M02-433

Gastroenterology Erb Agreement Hoffmann-La Roche Ltd. (Canada) 5,200

IMPROVE -ML21035 - Individualized Management with Pegasys RBV Offering Viral Eradication

Gastroenterology Kwan Agreement Gilead Sciences 8,434

GS-US-174-0108: A Phase II, Double-Blind, Multi-Center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil


Fumarate, and Entecavir in the Treatment of chronic Hepatitis B Subjects with Decomped

Gastroenterology Kwan Clinical Trial Idenix Pharmaceuticals Inc. 19,168

NV-02B-022: An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies

Gastroenterology Salh Grant Vancouver Coastal Health Research Institute (VCHRI)

60,000

Established Clinician: The role of integrin linked kinase in inflammatory bowel disease

Gastroenterology Salh Grant Geraldine Dow Ferry Endowment Fund

20,000

The role of integrin linked kinase in inflammatory bowel disease

Gastroenterology Steinbrecher Grant Heart and Stroke Foundation of British Columbia and Yukon

70,482

Activation of macrophage growth and survival pathways by oxidized LDL

Gastroenterology Tai Grant CIHR Doctoral Research Award JDD-83918 (Fellow: Tang, Michelle)

1,000

The role of SPARC in the activation of the extrinsic pathway in apoptosis for therapy-refractory tumors

Gastroenterology Tai Grant Cancer Research Society 150,000

Understanding the contribution of chemotherapy resistant cancer cells and the tumor microenvironment in gastrointestinal tumor metastasis

Gastroenterology Tai Grant Michael Smith Foundation for Health Research

80,000

Role of SPARC in cancer therapy

Gastroenterology Tai Grant Ferring Pharmaceuticals 500

Gastrointestinal Cancer Research

Gastroenterology Tai Grant Canadian Institutes of Health Research (CIHR)

85,592

The role of SPARC in Cancer Therapy Sensitization

Gastroenterology Tai Grant CIHR New Emerging Team Program CST-85477

282,498

Genomic, imaging and modeling approaches to advance population-based colorectal cancer screening

Gastroenterology Yoshida Clinical Trial Idenix Pharmaceuticals Inc. 4,445

NV-02B-011: A Randomized, Double-blind Trial of Telbivudine (LdT) vs Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

Gastroenterology Yoshida Agreement Hoffmann-La Roche Ltd. (Canada) 14,737

ML17908: A Phase IV Randomised, Multicentre, Efficacy and Safety Study Examining the Effect of Induction Dosing with the Combination of Peginterferon, alfa-2a and Ribavirin with Chronic Hepatitis C Infected with Hepatitis C Genotype I

Gastroenterology Yoshida Clinical Trial Human Genome Sciences Inc. 20,669

ALFR-HC-06: A Randomized, Multicentre, Open-label Study to Evaluate the Efficacy and Safety of Albuferon in Combination with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 2 or 3

Gastroenterology Yoshida Agreement Migenix Inc. 36,253

HCV-05-004: A Phase II Multicentre Extension Study to Evaluate the Safety and Efficacy of Celgosivir in Combination with Peginterferon alfa-2b, with or without Ribavirin, for an Additional 36 Weeks


Gastroenterology Yoshida Grant Geraldine Dow Ferry Endowment Fund

55,000

Endowment for inflammatory bowel disease research and education

Gastroenterology Yoshida Clinical Trial Human Genome Sciences Inc. 82,355

ALFR-HC-04: A Phase II-b Randomized, Multicenter, Active-controlled, Open-Label Study to Evaluate the Efficacy & Safety of Albuferon (recombinant human albumin-interferon alfa fusion protein) in Combination with Ribavirin in Interferon Alfa ......

Gastroenterology Yoshida Agreement Human Genome Sciences Inc. 86,889

ACHIEVE 1: A Phase III Randomized, Multicentre Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (pegasys or PEG-IFNa2a) in Combination with R

Gastroenterology Yoshida Clinical Trial Schering Canada Inc. 13,665

P03685: A Study to Assess Treatment with PEG-Intron and Rebetol in Naive Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response

Gastroenterology Yoshida Agreement Vertex Pharmaceuticals Inc. 32,387

VX06-950-106: A Phase II Study of Telaprevir (VX-950) in combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in subjects with Genotype 1 Hepatitis C who have not Achieved Sustained Viral Response with a Prior course of…

Gastroenterology Yoshida Agreement Human Genome Sciences Inc. 151,332

ACHIEVECA102: A Phase III Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in combination with Ribavirin compared with Peginterferon Alfa2a (PEG_INF a2a) in combination with Ribavirin

Gastroenterology Yoshida Clinical Trial Ortho Biotech 50

HEPC-AN-2: A Prospective Study to Evaluate the Hemoglobin Levels of Hepatitis C Virus Infected Patients Receiving Treatment with Combination Ribavirin/Interferon or Ribavirin/Pegylated Interferon

Gastroenterology Yoshida Agreement Hoffmann-La Roche Ltd. (Canada) 5,450

APPROACH: ML20090 - A Prospective Study of Peginterferon alfa-2a and Ribavirin: Outcomes Assessment in Chronic Hepatitis C Patients

General Internal Medicine

Khan Grant CIHR Operating Grant MOP-79329 39,000

Gender and ethnic differences in hypertension and Diabetes Mellitus


Khan Grant CIHR New Investigator IGN-80502 58,500

Gender and ethnic differences in hypertension and Diabetes Mellitus


Ma Grant UBC Faculty of Medicine 4,600

Faculty development initiative grants: Use of clinical simulators in teaching lumbar punctures in an internal medicine curriculum


Magee Grant CIHR: Institute of Human Development and Child/Youth Health

93,878

Birth under 29 weeks: improving outcomes for mothers and babies



Magee Grant MSFHR Scholar Award CI-SCH-57(02-1)

80,000

CHIPS -- Control of Hypertension In Pregnancy Study: A pilot trial


Magee Grant CIHR: IWRHTP Graduate Fellowship (Fellow: Massey, Kiran)

17,850

The Canadian Perinatal Network


Magee Grant CFRI: IWRHTP Graduate Fellowship (Fellow: Massey, Kiran)

3,000

The Canadian Perinatal Network


Ong-Lam Clinical Trial Montreal Heart Institute 3,715

IICT: Stop Pain Project - Study l: Assessment of Chronic Pain Burden and Management in Canada


Palepu Grant CIHR: Interdisciplinary Capacity Enhancement (ICE) Teams Grant Program

8,600

Interdisciplinary capacity enhancement grant in homelessness, housing and health


Palepu Grant MSFHR Scholar Award 100,000

Health research of vulnerable urban populations

Geriatric Medicine Adler Grant UBC VPR Research Development

Fund

10,000 Belief of combatants in Darfur - an exploration

Geriatric Medicine Beattie Agreement CIHR Operating Grant 6,020

Canadian Alzheimer's disease quality of life study

Geriatric Medicine Beattie Agreement CIHR Operating Grant 8,580

Canadian Alzheimer's disease quality of life study

Geriatric Medicine Cook Grant St. Paul's Hospital 50,000

Physician Scholars Program Salary Award

Geriatric Medicine Madden Grant CIHR Operating Grant 60,522

Exercise and cardiovascular control during upright tilt in older adults with Type-2 Diabetes

Geriatric Medicine McElhaney Clinical Trial CV Technologies Inc. 41,221

IICT: Efficiency and Safety of Cold-fX in the Prevention of Upper Respiratory Tract Infections in Community-dwelling Adults: A Multicentre, Randomized, Double-blind, Placebo-controlled Trial

Geriatric Medicine McElhaney Clinical Trial GlaxoSmithKline (Canada) Inc. 214,033

IICT Main: T-Cell Responses to Influenza Vaccination in Older Adults

Geriatric Medicine McElhaney Clinical Trial Merck Frosst Canada Ltd. 566

M.A.S.T.E.R. - Measuring Herpes Zoster and Post-Herpetic Neuralgia Assoc Burden of Illness and Health Care Utilization and Costs in Canada

Geriatric Medicine McElhaney Grant CIHR: International Opportunities Program - Development/ Planning Grant

24,990

The Roadmap to Improved Correlates of Protection Against Influenza

Geriatric Medicine Meneilly Clinical Trial Merck Frosst Canada Ltd. 28,000

IICT - Sitagliptin in the Elderly: Single Dose Study

Geriatric Medicine Meneilly Grant Various Sources 7,535

Diabetes in the Elderly


Geriatric Medicine Wong Grant Royal College of Physicians and Surgeons of Canada

16,000

Impact of a Novel, CanMEDS Focused Quality Improvement Curriculum on Knowledge Translation of Quality Improvement Skills Among Internal Medicine Residents

Hematology Broady Grant VGH and UBC Hospital Foundation -

Mentored Clinician Scientist Comp

50,000 Salary: Generation of antigen specific T regulatory cells for prevention of GVHD through induction of transplantation tolerance

Hematology Broady Grant British Columbia Transplant Society (BCTF-OPG-05-2005)

20,000

Extracorporeal Photopheresis: A Novel Approach to induce Transplant Tolerance?

Hematology Broady Grant Vancouver Coastal Health Authority 20,000

Matching Funds - Extracorporeal Photopheresis: A Novel Approach to Induce Transplant Tolerance

Hematology Broady Grant Vancouver Coastal Health Research Institute

10,000

VCHRI Global Collaboration Fund

Hematology Forrest Agreement Novartis Pharmaceuticals Canada Inc.

13,130

CAMN107A2303: A Phase III Multicentre, Open-label, Randomized Study of Imatinib versus Nilotinib in Adult Patients with Newly Diagnosed Philadelphia Chromosome Positive (PH+) chronic Myelogenous Leukemia in Chronic Phase (CML-CP)


26,957

CAMN107A2101: A Phase 1A/II Multicenter, Dose-escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients with Gleevec (imatinib)-resistant/interolerant CML in Chronic or Accelerated Phase or Blast Crisis+


13,495

CLBH589B2211: A Phase II, Multicentre Study of Oral LBH589 in Patients with Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia with Resistant Disease Following Treatment with at Least Two BCR-ABL Tyrosine Kinase Inhis

Hematology Forrest Agreement Bristol-Myers Squibb Co. (Canada) 650

CA180034 - A Randomized, Two-by-Two, Multicenter, Open-label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70mg Twice Daily or 100mg or 140 mg Once Daily in subjects with Chronic Phase Philadelphia Chromosome or BCR


12,935

CLBH589B2202: A Phase II, Multicentre Study of Oral LBH589 in Patients with Chronic Phase Chronic Myeloid Leukemia with Resistant Disease Following treatment with at Least Two BCR-ABL Tyrosine Kinase Inhibitors

Hematology Forrest Clinical Trial Bristol-Myers Squibb Co. (Canada) 39,987

CA180017: Randomized Multicenter Open-Label Study of BMS-354825 vs Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia who have disease that is resistant to Imatinib


Hematology Forrest Agreement Bristol-Myers Squibb Co. (Canada) 39,058

CA180035: A Randomized, Two-arm, Multicenter, Open-label Phase II Study of BMS354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid


25,121

CAMN107A2109: An Open-label, Multicentre, Expanded Access Study of Oral AMN107 in Adult Patients with Imatinib (Glivic/Gleevec - resistant) or - Intolerant Chronic Myeloid Leukemia in Blast Crisis Accelerated Phase or Chronic Phase…

Hematology Forrest Agreement Bristol-Myers Squibb Co. (Canada) 4,250

CA180033-038: A Study of Dasatinib (BMS-354825) in Subjects with Chronic Myelogenous Leukemia with Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant to…

Hematology Forrest Clinical Trial Bristol-Myers Squibb Co. (Canada) 99,002

CA180013: A Phase II Study to Determine the activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia who have Disease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or who ...

Hematology Hogge Clinical Trial EpiCept Corporation 12,455

A Multicenter, randomized, open-label study to evaluate the safety and efficacy of immunotherapy with subcutaneous maxamine (Histamine dichloride) plus proleukin vs. no treatment (standard of care) in patients with acute myeloid leukemia

Hematology Hogge Agreement Celmed BioSciences Inc. 62,695

CR-ECP-001 Safety, Biological and Clinical Efficacy of Two Intensity Levels of Theralux Extracorporeal Photochemotherapy in Subjects with Extensive Chronic GVHD Refractory or Intolerant to Standard Therapy

Hematology Hogge Agreement Xanthus Life Sciences 72,591

A Phase II Open-label Study of Amonafide L-Malate in Combination with Cytarabine in Subjects with Secondary Acute Myeloid Leukemia (AML)

Hematology Hogge Clinical Trial Vion Pharmaceuticals Inc. 28,475

CLI-037: A Phase III Randomized Study of Cloretazine (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse

Hematology Hogge Agreement Abbott Laboratories Ltd. (Canada) 19,630

M05-756: A Phase I Study of ABT-869 in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Hematology Hogge Agreement Therakos Inc. 27,727

UVADEX - CD-2: A Randomized, Controlled, Parallel-Group, Multicenter, Study of Extracorporeal Photoimmune Therapy with UVADEX for the Treatment of Patients with Newly Diagnosed Acute Graft-vs-Host Disease

Hematology Humphries Grant CIHR Postdoctoral Fellowship MFE-78150 (Fellow: Yung, Eric)

40,000

Salary: Novel Strategies for Genetic Modification and Expansion of Hematopoietic Stem Cells


Hematology Humphries Grant MSFHR Junior Gradiate Studentship ST-JGS-747(06-1)BM (Fellow: Miller, Michelle)

2,500

Use of recombinant fusion protein to expand hematopoietic stem cells in vitro and to elucidate mechanisms that determine the expansion and self-renewal potential of mouse fetal liver and adult hematopoietic stem cells

Hematology Humphries Grant Stem Cell Network (SCN) - Networks of Centres of Excellence (NCE)

39,500

Cell therapy for muscular disease


40,000

Cancer stem cell genomics and therapeutics


10,000

Targeted leukemic stem cell therapeutics

Hematology Humphries Grant MSFHR Postdoctoral Trainee Fellowship ST-PDF-261(04-1)BM (Fellow: Yung, Eric)

7,000

Novel strategies for genetic modification and expansion of hematopoietic stem cells

Hematology Humphries Grant CIHR Postdoctoral Fellowship MFE-78150 (Fellow: Yung, Eric)

5,000

Research Allowance: Novel strategies for genetic modification and expansion of hematopoietic stem cells


18,976

Development of technologies for the derivation, propagation and differentiation of hESC

Hematology Humphries Grant CIHR Team Grant Program RMF-82499

112,300

Analysis of stem cells using a new high-throughput technology for interrogating the molecular responses of single cells

Hematology Lansdorp Grant Stem Cell Network (SCN) - Networks of Centres of Excellence (NCE)

9,045

Development of technologies for the derivation, propagation, and differentiation of hESC

Hematology Lansdorp Grant Canada Foundation for Innovation Infrastructure Operating Fund 3857

5,156

CFI Infrastructure Operating Funds -- Stem Cell Centre -- Centre Share

Hematology Lansdorp Grant CFI Infrastructure Operating Fund 3857

95,009

CFI Infrastructure Operating Funds -- Stem Cell Centre -- Operations

Hematology Lansdorp Grant CIHR/Strategic: Request for Applications (Full) GMH-79042

490,225

Stem cells for the treatment of bone marrow failure

Hematology Lansdorp Grant CIHR Operating Grant MOP-38075 159,386

Replicative shortening of telomeres in human cells

Hematology Leger Clinical Trial Novartis Pharmaceuticals Corp. 1,352

(CSTI571ACA09) An Open-label, Randomized, Multicentre Study Comparing Gleevec (Imatinib) at Doses of 400mg and 800mg in Obtaining Major Molecular Response in Chronic Phase Patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia…

Hematology Leger Clinical Trial Wyeth-Ayerst Research 14,688

An Open-label, Randomized, Phase III Trial of Intravenous Temsirolimus (CC1-779) at Two Dose Levels Compared to Investigator's Choice Therapy in Relapsed, Refractory Subjects with Mantle Cell Lymphoma (MCL)


Hematology Leger Grant Novartis Pharmaceuticals Canada Inc.

2,500

Definition of the Frequency of Organ Toxicity and Death Related to Iron Overload in Red Cell Transfusion-dependent Patients with Myelodysplastic Syndrome (MDS)

Hematology Leitch Grant Novartis Pharmaceuticals Canada Inc.

7,700

Determination of the difference in neutropenia, thrombocytopenia, and leukemia-free survival in patients with myelodysplastic syndrome (MDS) according to receipt of iron chelation therapy (ICT)


12,000

Definition of the Frequency of organ toxicity and death related to iron overload in red cell transfusion-dependent patients with idiopathic myelofibrosis (IMF)

Hematology Leitch Clinical Trial Novartis Pharmaceuticals Canada Inc.

3,510

Protocol CAMN107ACA01: A Canadian Open-label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec(R))/Gleevec(R)) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated phase…

Hematology Leitch Clinical Trial Janssen-Ortho Inc. 8,455

(VELCADE) An Open-label, Randomized Study of VELCADE(R)/Melphalan/Predisone vs. Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma

Hematology Leitch Grant British Columbia Cancer Foundation 2,000

Molecular Diagnosis of Myelodysplastic Syndromes


8,200

Determination of the difference in red cell transfusion requirements in patients with myelodysplastic syndrome (MDS) according to receipt of iron chelation therapy (ICT)

Hematology Schrader Grant CIHR - Canada Research Chair Tier I 100,000

Canada Research Chair Tier I in immunology - John Schrader

Hematology Shepherd Clinical Trial Novartis Pharmaceuticals Canada Inc.

1,840

A phase III study of ST1571-106 versus Interferon-a (IFN-A) combined with Cytarabine (Ara-C0) in patients with newly diagnosed previously untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)

Hematology Smith Grant Canada Research Chair Tier II (CIHR) 950-203507

41,667

Canada Research Chair in cell therapies for Dr Clayton Smith

Hematology Smith Grant Stem Cell Network (SCN) - Networks of Centres of Excellence (NCE)

25,000

Canadian cord blood stem cell initiative

Hematology Smith Grant British Columbia Transplant Society 30,000

Diagnosis of graft vs. host disease using high throughput flow cytometry

Hematology Smith Grant National Institutes of Health Research Grant 1 R01 CA108752-01A2

234,950

Transplantation of G-CSF Stimulated Marrow vs Blood


Hematology Smith Agreement AnorMed Inc. 4,167

A Multicentre, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 plus G-CSF vs. C-CSF Plus Placebo to Mobilize and Collect 5x10 CD34+ Cells/kg in Non-Hodgkins Lymphoma Patients for Autologous Transplantation

Hematology Smith Clinical Trial AnorMed Inc. 17,069

AMD3100-C201: Treatment with AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF

Hematology Smith Agreement AnorMed Inc. 2,780

Protocol 3102CA: A Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (241ug/kg) plus G-CSF vs. G-CSF Plus Placebo to Mobilize and collect 6/s0 CD34+ Cells/kg in Multiple Myeloma Patients…

Hematology Song Agreement Gentium S.P.A. 1,300

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoietic Stem Cell Transplant Patients: A Historically-Controlled, Multicentre Phase III Study to Determine Safety & Efficacy

Hematology Song Grant National Cancer Institute of Canada 3,000

A Randomized Phase III Study of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Hematology Song Agreement Celgene Corp. 55,307

MM016: A Multicentre, Single-arm, Open-label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated subjects With Multiple Myeloma

Hematology Song Agreement Novartis Pharmaceuticals Canada Inc.

13,520

CLBH589B2203: A Phase II Study of LBH589 in adult patients with Multiple Myeloma who have received at least two prior lines of therapy and whose disease is refractory to the most recent line of therapy

Hematology Sutherland Agreement Centocor Inc. 117,680

Protocol C0328T06: A Phase II Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO328 (Anti-IL-6 Monoclonal Antibody) and Velcade vs. Velcade Alone in Subjects with Relapsed or Refractory Multiple Myeloma

Hematology Sutherland Agreement Ortho Biotech 14,820

DOXIL-MMY-2001: A Phase II Study to Assess the Safety and Efficacy of DBd combination Therapy (DOXIL/CAELYX) VELCADE and Dexamethasone for Previously Untreated Multiple Myeloma Patients

Hematology Sutherland Clinical Trial Janssen-Ortho Inc. 48,027

DOXIL-MMY-3001: A Randomized, Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and Velcade (bortezomib) or Velcade Monotherapy for the Treatment of Relapsed Multiple Myeloma


Hematology Toze Clinical Trial Celmed BioSciences Inc. 10,400

TH9402/II/NHL/002: A Phase II Study of Autologous Transplantation with TH9402 Photodynamic Cell Processing of the Progenitor Cell Graft for Patients with Non-Hodgkin's Lymphoma (Screening Evaluation)

Hematology Vickars Clinical Trial Novartis Pharmaceuticals Canada Inc.

240

ICL670 Exjade: A Study to Provide Expanded Access of EXJADE (deferasirox) to Patients with Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated with Other Locally…

Hematology Vickars Grant Hoffmann-La Roche Ltd. (Canada) 10,000

IICT: Review of Patients at St. Paul's Hospital With Immune Phenomena Treated With Rituximab; Clinical and Laboratory Characteristics and Outcome - Retrospective Chart Review (10306C)

Hematology Vickars Grant Hoffmann-La Roche Ltd. (Canada) 2,730

Protocol McMaster R-ITP: A Randomized, Double-blind, Placebo-controlled Pilot Trial of Rituximab for Non-splenectomized Adults with Acute Immune Thrombocytopenic Purpura Receiving Standard Treatment (R-ITP)

Hematology Vickars Clinical Trial Novartis Pharmaceuticals Canada Inc.

96,570

(EXJADE - CICL670AUS03) An Open-label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-risk and INT-1, Myelodysplastic Patients Using Serum Ferritin Monitoring

Hematology Vickars Grant Association of Hemophilia Clinic Directors of Canada

2,000

A survey of factor prophylaxis in patients with Hemophilia followed in Canadian Hemophilia treatment centers

Infectious Diseases Av-Gay Grant MSFHR: Postdoctoral Trainee

Fellowship ST-PDF-111(05-1)BM (Fellow: Bach, Horacio)

23,875

Molecular Analysis of Mycobacterium Tuberculosis Protein Phosphatase

Infectious Diseases Av-Gay Grant CIHR Operating Grant 95,098

Molecular analysis of Mycobaterium tuberculosis protein kinases and phosphatases

Infectious Diseases Av-Gay Contract Nitric Bio Therapeutics Inc. 24,981

Antimicrobial Activity of Gaseous Nitric Oxide

Infectious Diseases Av-Gay Contract Pulmonox Medical Inc. 18,750

SA: The Effect of Nitric Oxide on Viral Infection

Infectious Diseases Av-Gay Grant British Columbia Lung Association 21,000

Mycobacterium tuberculosis protein Kinase J: Role in infectious and antibiotic resistance

Infectious Diseases Av-Gay Contract Enox Biopharma Inc 25,131

SC: Coating and In vitro Examination of Tympanostomy Tubes for Ottis Media

Infectious Diseases Av-Gay Grant Vancouver Coastal Health Authority 10,000

Role of cholesterol in tuberculosis infection

Infectious Diseases Av-Gay Grant VGH Foundation - TB VETS 70,000

Tuberculosis research


Infectious Diseases Brunham Grant CIHR Rx & D Research Program Fellowship (Fellow: Zaharik, Michelle)

20,000

Developing a Chlamydia trachomatis vaccine by optomizing dendritic cell responses

Infectious Diseases Brunham Contract Genome British Columbia 150,000

CRA: Accelerated Chlamydia trachomatis Immunoproteomic Vaccine Enterprise (ACTIVE)

Infectious Diseases Brunham Contract Sanofi Pasteur Ltd. 462,000

CRA: Biological and Immunogenic Evaluation of C. trachomatis Vaccine Candidate Antigens and Formulations

Infectious Diseases Brunham Grant CIHR Rx & D Research Program Fellowship (Fellow: Zaharik, Michelle)

2,500

Developing a Chlamydia trachomatis vaccine by optomizing dendritic cell responses

Infectious Diseases Brunham Agreement National Institutes of Health 65,730

Inflammation and ovarian cancer

Infectious Diseases Brunham Agreement National Institutes of Health 103,425

Comparative genomics of the Chlamydiaceae family of obligate intracellular parasites: a study of new laboratory methods to better understand Chlamydia infection

Infectious Diseases Brunham Grant CIHR Proof of Principle 150,000

Accelerated Chlamydia Trachomatis Immunoproteomic Vaccine Enterprise

Infectious Diseases Burdge Clinical Trial CIHR Randomized Controlled Trials 875

Predictors of Antiretroviral Pharmacokinetics in HIV-Infected Women with Virologic Suppression on Combination Antiretroviral Therapy

Infectious Diseases Cherkasov Contract Genome British Columbia - Full Proposal

96,000

Functional Genomics for Emerging Infectious Diseases

Infectious Diseases Cherkasov Grant CIHR Fellowship MFE-76560 (Fellow: Ban, Fuqiang)

16,822

Salary: Design and discovery of novel antimicrobial peptides as effective therapeutics against drug-resistant bacteria

Infectious Diseases Cherkasov Grant MSFHR: Senior Graduate Studentship Award ST-SGS-362(06-1)BM (Fellow: Hsing, Michael)

2,500

Bioinformatics of sequence indels: novel applications for protein network analysis, drug target identification and drug development

Infectious Diseases Cherkasov Grant CIHR Doctoral Research Award MDR-75875 (Fellow: Fjell, Christopher)

1,000

Quantitative Structure-Activity Relationships and Machine Learning Techniques for Identification of Novel Antimicrobial Agents

Infectious Diseases Chow Grant CIHR: MD/PhD Program Studentship MMP-71794 (Fellow: Heslop, Claire)

1,000

Biomarkers of oxidative stress: An evaluation of nutrient-gene interactions in coronary artery disease

Infectious Diseases Chow Grant CIHR: MD/PhD Program Studentship MMP-65952 in collaboration w/ the Institute of Circulatory & Respiratory Health (Fellow: Heine, Heather)

1,000

Myocardial regeneration with hematopoietic stem cells

Infectious Diseases Chow Grant CIHR: MD/PhD Program Studentship MMP-71793 (Fellow: Berkhout, Susan)

1,000

Life at the margins: An interdisciplinary analysis of the social determinants of HIV/AIDS and women's health


Infectious Diseases Chow Grant CIHR: MD/PhD Program Studentship MDG-79753 (Fellow: Astanehe, Arezoo)

44,000

CIHR MD/PhD Grants for Arezoo Astanehe and Brennan Eadie

Infectious Diseases Chow Grant CIHR: MD/PhD Program Studentship MMP-65951 (Fellow: Joe, Aaron)

1,000

Molecular determinants of stem cell trafficking

Infectious Diseases Chow Grant CIHR: MD/PhD Program Studentship IMD-78843 (Fellow: Young, Fiona)

1,000

The role of ABCA1 in the central nervous system

Infectious Diseases Chow Grant MSFHR Grant-in-Aid OT-GIA-001056 22,000

MD/PHD Program Support

Infectious Diseases Chow Grant CIHR: MD/PhD Program Studentship MMP-58313 (Fellow: Coburn, Bryan)

1,000

The pathogenomics of salmonella infection

Infectious Diseases Chow Grant CIHR: MD/PhD Program Studentship MMP-58293 (Fellow: Brunham, Liam)

1,000

Identification and validation of genes modulating LDL cholesterol in humans

Infectious Diseases Hmama Grant CIHR: HIV/AIDS Research Program MOP-84557

85,737

Role of the Mycobacterial Lipoamide Dehydrogenase in the Pathogenesis of Tuberculosis

Infectious Diseases Hmama Grant British Columbia Lung Association 30,000

Role of the Macrophage Receptor CD14 in Anti-TB Immunity

Infectious Diseases Hmama Grant MSFHR Scholar Award 20,000

Molecular study of interaction between Mycobacterium tuberculosis and the macrophage endosomal compartment: an approach to identify mycobacterial virulence factors

Infectious Diseases Hmama Grant MSFHR Career Investigator Program 60,000

Translational TB research: Novel vaccine and drug target

Infectious Diseases Hmama Grant Vancouver Coastal Health Authority 85,000

Salary support: Dr. Hmama

Infectious Diseases Hmama Grant VGH Foundation - TB VETS 75,000

Tuberculosis research

Infectious Diseases Hmama Grant VCHA 10,000

Enhancing the Efficacy of the Vaccine Mycobacterium Bovis BCG

Infectious Diseases Isaac-Renton Grant CIHR Doctoral Research Award 2,000

Molecular epidemiology of giardia lamblia in British Columbia's water supplies

Infectious Diseases Nandan Contract Pacific Pharma Technologies Inc. 16,500

Screening Assays and Consulting Services

Infectious Diseases Patrick Grant MSFHR - HSPR Operating Grant - Full Application

49,838

Changing Prescription Practices to Limit Selection for Resistant Organisms: A Population and System Approach

Infectious Diseases Patrick Grant Provincial Health Services Authority 62,000

Research operating account

Infectious Diseases Patrick Grant CIHR: HIV/AIDS Research Program 96,988

Development of an HIV/AIDS Prevention Intervention for Indoor Sex Workers and Their Partners


Infectious Diseases Patrick Grant CIHR Doctoral Research Award IDR-76898 (Fellow: McCarthy, Sheila)

1,000

Salary-HIV and Hepatitis C transmission networks in a cohort of injection drug users in Vancouver's downtown eastside: How structure and context matter

Infectious Diseases Phillips Clinical Trial BioAlliance Pharma 3,444

BA/2004/01/04: A Comparative Randomized, Double-Blind, Double-Dummy, Multicenter Study of the Efficacy and Safety of Miconazole Lauriad(R) 50mg Administered Once a Day and Mycelex(R) Troches (Clotrimazole 10mg) Administered Five Times a Da

Infectious Diseases Reiner Grant CIHR: Institute of Infection and Immunity -- Operating Grant

97,451

Macrophage cell regulation

Infectious Diseases Reiner Contract Genome British Columbia - Full Proposal

1,790,826

Functional Genomics for Emerging Infectious Diseases

Infectious Diseases Reiner Grant MSFHR: Junior Graduate Studentship Award ST-JGS-094(05-1)BM (Fellow: Thi, Emily)

2,500

Identification of Mycobacterium Tuberculosis Virulence Effector Proteins by Pathogen Effector Protein Screening in Yeast

Infectious Diseases Reiner Grant VCHA - Venture Grants (VGH & UBC Foundation In It For Life)

30,000

Identification of M.Tuberculosis and Chlamydia Trachomatis Effector Proteins Using a Genetic Screen in Yeast

Infectious Diseases Reiner Grant VCHA - Bridge Funding 10,000

Macrophage cell regulation

Infectious Diseases Reiner Grant VGH and UBC Hospital Foundation 98,000

PREPARE Project

Infectious Diseases Bowie Grant Vancouver Coastal Health Research Institute (VCHRI) - Team Grants

29,400

Incision and Drainage Alone vs Incision and Drainage and Trimethoprim-Sulfamethoxazole/Rifampin for Soft Tissue Abscesses Caused by Community Associated…

Infectious Diseases Steiner Grant Crohn's and Colitis Foundation of Canada

97,000

The Role of Bacterial Flagellin as an Inflammatory Stimulus in INflammatory Bowel Disease

Infectious Diseases Steiner Grant VCHA - Venture Grants (VGH & UBC Fdn In It For Life)

29,755

Establishment of a Rodent Model of Enteroagregative Escherichia Coli Enterocolitis

Infectious Diseases Steiner Grant CIHR Operating Grant MOP-64355 in collaboration w/ The Institute of Infection and Immunity (CIHR)

78,436

Mechanisms of toll-like receptor-5 signaling in response to bacterial Flagellin

Infectious Diseases Steiner Grant CIHR New Investigator 58,500

Mechanisms of Innate Immune Signaling by Enteroaggregative E. coli Flagellin

Infectious Diseases Steiner Grant CIHR 50,000

New emerging team grant in clinical autoimmunity

Infectious Diseases Tyndall Clinical Trial Merck and Co. Inc. 281,340

Protocol V520-023 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Proof-of-Concept Study to Evaluate the Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd5 HIV


Infectious Diseases Tyndall Grant MSFHR: Junior Graduate Studentship Award ST-JGS-401(05-1)POP (Fellow: Berkhout, Susan)

1,500

Life at the margins: Understanding social determinants of HIV/AIDS on Women's Health through multidisciplinary translational research

Infectious Diseases Tyndall Grant MSFHR: Postdoctoral Trainee Fellowship ST-PDF-435(05-1)POP (Fellow: Orchard, Treena)

10,472

To each her own: sex work typologies, intimate relationships, and their impact on HIV risk for female sex workers in Vancouver DTES

Infectious Diseases Tyndall Grant MSFHR: Senior Graduate Studentship Award ST-SGS-473(05-1)POP (Fellow: Small, William)

3,417

An examination of injection drug use sites: the influence of social and physical context upon drug-related harms and public health interventions

Infectious Diseases Tyndall Grant CIHR: Strategic Training Program Grant - Institute of Aging

310,500

UBC Training program for translational research in infectious diseases

Infectious Diseases Tyndall Grant CIHR: HIV/AIDS Research Program 90,420

MAKA Initiative: HIV prevention and care among women survival sex workers

Infectious Diseases Tyndall Grant MSFHR Senior Scholar Award CI-SSH-097 (05-1)HSR

100,000

An interventional HIV research program to reduce transmission and enhance antiretroviral treatment outcomes among highly marginalized populations

Infectious Diseases Tyndall Grant British Columbia Centre for Excellence in HIV/AIDS

125,157

Salary support for Dr. Mark Tyndall

Infectious Diseases Tyndall Grant CIHR: HIV/AIDS Research Program 249,033

Enhancing the uptake and sustainability of HIV care & antiretroviral therapy among survival sex workers

Infectious Diseases Tyndall Grant CIHR Doctoral Research Award IDR-80936 (Fellow: Small, William)

1,000

Examination of injection drug use sites: the influence of social and physical context upon HIV risk, drug-related harms and public health interventions

Medical Oncology Gelmon Grant Michael Smith Foundation for Health

Research: Postdoctoral Trainee Fellowship (Fellow: Lane, Kirstin)

24,375

Effect of Chronic Exercise on Lymphatic Function

Medical Oncology Gill Grant Canadian Institutes of Health Research (CIHR): CIHR Rx & D Research Program - Fellowships (Fellow: Lim, Howard)

5,000

Research allowance: A phase II study of second line Sunitinib in previously treated patients with unresectable locally advanced or metastatic pancreatic cancer

Medical Oncology Gill Grant Canadian Institutes of Health Research (CIHR): CIHR Rx & D Research Program - Fellowships (Fellow: Lim, Howard)

32,500

Salary: A phase II study of second line Sunitinib in previously treated patients with unresectable locally advanced or metastatic pancreatic cancer

Medical Oncology Klimo Clinical Trial Novartis Pharmaceuticals Canada Inc.

9,542

A Randomized, Multicenter Study Comparing Prolonged Primary Systemic Endocrine Therapy with Letrozole (Femara) Alone or in Combination with Zoledronic Acid (Zometa) in Early Breast Cancer (NEOadjuvant study in CANada)


Medical Oncology Klimo Agreement Bayer Pharmaceuticals 14,891

Protocol 11961: A Randomized, Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY 43-90006) in chemonaive Patients with Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Nephrology Chiu Clinical Trial AstraZeneca Canada Inc.

4,240 Protocol PLANET II: Prospective Evaluation of Proteinuira and Renal Function in Non-Diabetic Patients With Progressive Renal Disease

Nephrology Chiu Clinical Trial AstraZeneca Canada Inc. 2,943

A double-blind, randomised, dose-ranging, multicentre, Phase III-b study to evaluate the efficacy and safety of high doses of candesartan cilexetil (Atacand)on the reduction of proteinuria in the treatment of subjects with hypertension and…

Nephrology Chiu Clinical Trial AstraZeneca Canada Inc. 4,240

Protocol PLANET I: Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

Nephrology Duncan Clinical Trial AstraZeneca Canada Inc. 2,730

4522IL/0096 (AURORA) A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: An Assessment of Survival & Cardiovascular Events: Double-blind Randomized Multicentre Phase III-b Parallel-group Study to Compare the ....

Nephrology Duncan Clinical Trial Merck and Co. Inc. 14,751

SHARP: Study of Heart and Renal Protection

Nephrology Gill Clinical Trial Novartis Pharmaceuticals Canada Inc.

3,000

Protocol MyGain: A 4-week, Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Gastrointestinal Safety and Tolerability of Myfortic and MMF (Cellcept) when Administered in Combination with Calcineurin Inhibitors in…

Nephrology Gill Clinical Trial Novartis Pharmaceuticals Canada Inc.

46,157

A 24-week Feasibility Study to Evaluate Replacement of Calcineurin Inhibitor (CNI) With Simulect In CNI Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids (REPLACE study)

Nephrology Gill Clinical Trial CIHR Randomized Controlled Trials 7,000

IICT: ACE-Inhibition for the Preservation of Renal Function and Patient Survival in Kidney Transplantation

Nephrology Gill Grant MSFHR Scholar Award 80,000

Access to kidney transplantation in B.C. and Alberta

Nephrology Gill Grant CIHR Operating Grant 107,149

Access to kidney transplantation in B.C. and Alberta

Nephrology Gill Grant Canadian Institutes of Health Research

5,850

The Long-term Medical and Psychosocial Implications of Becoming a Living Kidney Donor: A Canadian Prospective Pilot Study


Nephrology Jung Clinical Trial St. Joseph's Hospital and Medical Center

5,436

IICT: A Randomized Controlled Trial of Mycophenolate Mofetil in Patients with IgA Nephropathy (MMF/IgAN Study)

Nephrology Jung Clinical Trial AstraZeneca UK Ltd. 6,897

(AURORA) A double blind, randomised, multicentre, phase III-b, parallel-group study to compare the effects of Rosuvastatin (10mg oral) with placebo on assessment of survival and cardiovascular events when given to subjects with end-stage renal failure on chronic haemodialysis treatment

Nephrology Keown Contract Genome British Columbia 329,918

CRA: Better Biomarkers of Acute and Chronic Allograft Rejection

Nephrology Keown Grant CIHR: Partnership for Health System Improvement PHE-81967

75,000

A pilot project for health systems improvement to facilitate live donor and pre-emptive renal transplantation in chronic kidney disease

Nephrology Keown Clinical Trial Novartis Pharmaceuticals Canada Inc.

3,624

CERL080AUS51: A 4 Week, Multicenter, Double-Blind, Randomized, Parallel Group Study to Compare the Gastrointestinal Safety and Tolerability of Myfortic and MMF (Cellcept) when Administered in Combination with Calcineurin Inhibitors in Renal

Nephrology Keown Contract Providence/ St. Paul's Hospital Foundation

70,935

Better Biomarkers in Transplantation

Nephrology Kiaii Clinical Trial Hoffmann-La Roche Ltd. (Canada) 11,971

Short Title: CERA for Hemodialysis Population (version 1.1) A Randomized, Controlled, Open-Label, Multi-Center, Parallel-Group Study to Compare the Efficacy and Safety of RO0503821 With That of Darbepoetin Alfa Administered Intravenously

Nephrology Kiaii Clinical Trial University of Calgary 4,857

IICT: Prevention of Catheter Lumen Occlusion with rT-PA (Recombinant Tissue Plasminogen Activator) Versus Heparin (Pre-CLOT): A Double Blind Randomized Trial

Nephrology Levin Grant Canadian Institutes of Health Research

160,232

Canadian Prevention of Renal and Vascular Endpoints Trial

Nephrology Levin Clinical Trial Janssen-Ortho Inc. 15,000

A study to determine the impact of Hgb maintenance and other interventional strategies to prevent or delay the progression of left ventricular mass growth in subjects with early renal insufficiency

Nephrology Levin Grant Ortho Biotech 1,250

IICT:REPEAT Study: Resistance to Erythropoetin Effectiveness Algorithm Trial

Nephrology Levin Clinical Trial Genzyme Corp. 30,000

IICT: Peritoneal Dialysis Research Program

Nephrology Levin Grant Various Sources 31,000

NERC


Nephrology Levin Clinical Trial Merck and Co. Inc. 247,848

Study of Heart and Renal Protection (SHARP)

Nephrology Quamme Grant CIHR Operating Grant 100,000

Studies of Renal Magnesium Transport

Nephrology Shapiro Clinical Trial Wyeth Research 10,926

0468H1-407-WW: A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen versus Continuation of a Calcineurin Inhibitor-based Regimen

Nephrology Wong Grant Show Chwan/VHHSC Fund 52,891

Vasoactive peptides in congestive heart failure

Nephrology Yeung Clinical Trial St. Joseph's Hospital and Medical Center

3,789

IICT: A Randomized Controlled Trial of Mycophenolate Mofetil in Patients with IgA Nephropathy

Neurology Barton Grant CIHR Operating Grant MOP-81270

73,587 The context and effects of trial history on saccades and their status in neurological disorders

Neurology Barton Grant Canada Research Chair Tier II (CIHR) 950-202111

100,000

Canada Research Chair for Dr. Jason Barton in Neuropsychology of vision and eye movements

Neurology Barton Grant National Institutes of Health 5R01MH069898-05

325,044

Perceptual encoding and imagery in prosopagnosia

Neurology Barton Grant MSFHR Senior Scholar Award CI-SSH-035(03-1) CLIN

15,000

Neuropsychology of vision and eye movements

Neurology Barton Grant MSFHR Postdoctoral Trainee Fellowship ST-PDF-180(06-1)CLIN (Fellow: Iaria, Giuseppe)

21,208

Topographical disorientation as a predictor of Alzheimer's Disease in patients affected by mild cognitive impairment

Neurology Barton Grant MSFHR Postdoctoral Trainee Fellowship ST-PDF-339(05-1)CLIN (Fellow: Wieske, Van Zoest)

32,500

Stimulus-driven Control in Visual Neglect: The Role of Awareness

Neurology Barton Grant CIHR: Doctoral Research Awards CGD-80369 (Fellow: Fox, Christopher)

5,000

Facial identity and expression perception following cerebrovascular infarction

Neurology Barton Grant CIHR Operating Grant MOP-77615 101,312

Processing of face recognition in patients with occipitotemporal lesions after posterior cerebral infarction

Neurology Barton Grant Canadian Institutes of Health Research (CIHR)

60,000

Face expression and identity processing in the occipitotemporal cortex

Neurology Barton Grant BC Network for Aging Research 4,900

Navigating in the elderly: Behavioural and MRI correlates of aging effects on cognitive maps

Neurology Barton Grant Department of Medicine Academic Enhancement Fund

29,453

Interactive case-based approach to neuro-ophthalmologic education on the internet

Neurology Cashman Contract Pall Corporation 39,000

Detection of Prions in Blood


Neurology Cashman Grant PrioNet - Networks of Centres of Excellence (NCE)

270,000

Immunotheraphy of CJD

Neurology Cashman Grant Donation 557,000

Allen T. Lambert Neural Research Fund: ALS Transplantation

Neurology Cashman Grant PrioNet - Networks of Centres of Excellence (NCE)

304,160

Pathogenesis & Bioassay Platform

Neurology Cashman Contract Amorfix Life Sciences Ltd. 300,000

Prion-like misfolding of Superoxide Dismutase I in Amyotrophic Lateral Sclerosis

Neurology Cashman Grant UBC VPR Research Development Fund & VCHA

126,240

UBC PrioNet Canada operation support

Neurology Cashman Grant Canada Research Chair Tier I (CIHR) 200,000

Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases for Dr. Neil Cashman

Neurology Chapman Agreement Pfizer Canada Inc. 13,808

Protocol A0081064: A 9-week, randomized, double-blind, placebo-controlled, multicenter, study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic pain

Neurology Chapman Clinical Trial Takeda Global Research and Development

39,588

01-05-TL-128-006 An Open-label, multi-centre Study to Evaluate the Safety of Long-term Administration of TAK28 in Subjects with Mild to Moderate Diabetic Peripheral Neuropathy

Neurology Chapman Clinical Trial Wyeth-Ayerst Canada Inc. 325

Protocol 0912A2-212-NA: Multicenter Randomized Double-blind Placebo-controlled Study of 3 Fixed Doses of EAA-090 in Adult Outpatients with Neuropathic Pain Associated with Diabetic Neuropathy

Neurology Chapman Agreement Takeda Global Research and Development

161,248

01-06-TL-583-006: A Phase 2, Randomized, double-Blind, Placebo-Controlled, Dose Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects with Mild to Moderate Diabetic Peripheral Neuropathy

Neurology Devonshire Grant Health Science Donations 5,000

MS COSTAR Data Entry for the Genetic Susceptibility to MS Study

Neurology Devonshire Clinical Trial Novartis Pharmaceuticals Canada Inc.

140,041

CFTY720D2301: A 24-Month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study comparing Efficacy and Safety of FTY720 1.25mg and 0.5 mg Administered Orally Once Daily vs. Placebo in Patients with Rel/rem MS


14,690

CFTY720D2201E1: Ext. to CFTY720D2201: Extension of the Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicentre Study Evaluating Safety Tolerability & Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients with Relapsing..


Neurology Devonshire Clinical Trial GW Pharmaceuticals PLC 5,965

GWMS0501: A Double-blind, Randomised, Placebo-controlled, Parallel-group Study of Sativex when added to the Existing Treatment Regimen in the Relief of Central Neuropathic Pan in Subjects with Multiple Sclerosis


150,722

CFTY: 720D2302 A 12 month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily vx. Interferon B-1a...

Neurology Devonshire Clinical Trial Biogen Idec Inc. 50,842

101-MS-322: An Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-initiation of Dosing in Multiple Sclerosis Subjects who have Completed Studies C1801, C-1802, or C-1803 and ......

Neurology Doudet Contract Bayer HealthCare Pharmaceuticals Inc. USA

179,370

In vivo PET and behavioural study of the effect of striatal implantation of Retinal Pigment Epithelial cells in a primate model of Parkinson' disease

Neurology Doudet Grant Parkinson Society Canada: Basic Research Fellowship (Fellow: Landau, Anne)

13,333

Evaluation of the role of monoamines in electroconvulsive therapy in an animal model of Parkinson's Disease

Neurology Doudet Grant CIHR Team Grant Program CTP-79851

84,588

CIHR Team in Parkinson's Disease: Core D - Animal Core

Neurology Doudet Grant MSFHR Senior Graduate Studentship Award ST-SGS-367(06-1)BM (Fellow: Flores, Joe)

2,500

In Vivo Evaluation of the Potential Role of Anti-inflammatory Factors Involved in the Survival and Mechanism of Action of hRPE-Cell Implants for Parkinson's Disease

Neurology Feldman Grant MSFHR Senior Graduate Studentship Award ST-SGS-350(05-1)CLIN (Fellow: LaMarre, Amanda)

2,500

Cognitive and Behavioural Characterization of Individuals Genetically at Risk for Frontotemporal Dementia

Neurology Feldman Grant Lundbeck Canada Inc. 40,780

Clinical Meaningfulness In Alzheimer's Disease Treatment (CLIMAT) Scale

Neurology Feldman Grant CIHR Operating Grant MOP-74580 371,299

Frontotemporal dementia with ubiquinated inclusions: Clinical, genetic, and pathological characterization

Neurology Feldman Clinical Trial ONO Pharma USA Inc. 2,931

ONO-2506POU010: Double-blind, Phase II Safety and Efficacy Evaluation of ONO-2506PO in Patients with Mild to Moderate Alzheimer's Disease

Neurology Feldman Grant VCHA Venture Grants 29,780

Development of the Clinical Meaningfulness in Alzheimer Disease (CLIMAT) Scale

Neurology Feldman Clinical Trial Sanofi-Synthelabo Canada Inc. 23,270

LTS5283: Long-Term Safety Extension of Phase II Study EFC5286 of SR57667B in Patients with Mild-to-Moderate Alzheimer's Disease


Neurology Feldman Agreement Myriad Genetics Inc. 27,666

MPC-7869-05-010: Phase 3 Multinational, Randomized, Double-Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia

Neurology Feldman Agreement GlaxoSmithKline (Canada) Inc. 3,000

AVA102670: (REFLECT-3) A 54-week Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (extended release tablets) as Adjunctive Therapy to Acetycholinesterase Inhibitors on Cognition

Neurology Feldman Grant Alzheimer Society & Mr David Townsend

100,000

Alzheimer Research

Neurology Feldman Grant Alzheimer Society of BC Professorship

48,925

Alzheimer Research

Neurology Feldman Clinical Trial National Institutes of Health 53-00-ADNI-PIB

1,945

IICT (Gov't.): Alzheimer Disease Neuroimaging Initiative (ADNI)

Neurology Gibson Clinical Trial Eli Lilly Canada Inc. 785

Protocol B7A-MC-MBBR: LY333531 Treatment of Peripheral Neuropathy in Patients with Diabetes: A Phase 3 Pivotal Clinical Trial

Neurology Hashimoto Grant Donations for Health Science Research

1,250

Clinical Research in Multiple Sclerosis

Neurology Illes Grant Canada Research Chair Tier I (CIHR) 150,000

Canada Research Chair in neuroethics for Dr. Judy Illes

Neurology Illes Grant Canada Foundation for Innovation 349,967

National Core for Integrated Neuroethics in Canada (NCINC) at UBC

Neurology Illes Grant Canadian Institutes of Health Research (CIHR)

266,666

National core for integrated neuroethics in Canada (NCINC)

Neurology Illes Grant Foundation for Ethics and Biotechnology

55,000

Bioethical Landscape of Neurodegenerative Diseases Research and Treatment

Neurology Johnston Clinical Trial NMT Medical Inc. 10,000

A prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the Starflex (R) septal closure system versus best medical therapy in patients with a stroke and/or transient ischemic attack due to presumed pa

Neurology Kastrukoff Grant Canadian Institutes of Health Research (CIHR)

98,400

Natural killer (NK) and natural killer T (NKT) cells in Herpes simplex virus Type 1 (HSV 1) infections in mice

Neurology Kastrukoff Clinical Trial Teva Neuroscience Inc. (US) 8,418

GA9016: A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study, to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40mg/ml to that of Glatiramer Acetate Injection 20mg/ml Administered...


Neurology Kastrukoff Grant Donations for Health Science Research

300

Virology Research

Neurology Krieger Clinical Trial Sanofi Pasteur Ltd. 11,400

Long term safety and tolerability study of SR57746A in patients with Amyotrophic Lateral Sclerosis

Neurology McKeown Grant Natural Sciences and Engineering Research Council of Canada (NSERC)

54,988

Making the connection: methods to infer functional connectivity in brain studies

Neurology McKeown Agreement National Parkinson Foundation (US) 67,523

01 Account- Designation as an National Parkinson Foundation, Centre of Excellence

Neurology McKeown Grant Michael Smith Foundation for Health Research

1,458

Dynamic suppression of pathological brain oscillations in Parkinson's disease with virtual environments

Neurology McKeown Grant NSERC/CIHR: Collaborative Health Research Projects CHRPJ 323602-06 with SFU

54,988

Making the connection: methods to infer functional connectivity in brain studies

Neurology McKeown Grant CIHR: Doctoral Research Awards CGD-80403 (Fellow: Palmer, Samantha)

5,000

Research Allowance - Changes in effective connectivity in Parkinson's Disease: Disentangling compensatory mechanisms from effects of disease

Neurology Oger Grant Dr. Schlegel Healthworld AG 30,000

Setting-up, validating and evaluating the clinical usefulness of laboratory tests to measure antibodies to interferon in multiple-sclerosis patients

Neurology Oger Clinical Trial BioMS Technology Corp. 113,063

MBP8298-SP-02: An Open-label Follow-up Study to Assess the Ongoing Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis

Neurology Oger Clinical Trial BioMS Technology Corp. 329,111

MBP8298-01: A Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis

Neurology Oger Clinical Trial ACORDA Therapeutics MS-F203 EXT

35,095

MS-F203 Extension Study: An Open-label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with MS who Participated in the MS-F203 Trial

Neurology Oger Clinical Trial Various Pharmaceutical Companies 57,313

Setting-up, Validating and Evaluating the Clinical Usefulness of Laboratory Tests to Measure Antibodies to Interferon in Multiple Sclerosis Patients

Neurology Oger Grant Multiple Sclerosis Society of Canada: Career Development Award for Helen Tremlett

50,000

The MaMS Study, Malignancy and Multiple Sclerosis: incidence and impact of beta-interferon treatment

Neurology Oger Grant Donations for Health Science Research

7,170

Myasthenia Gravis Research

Neurology Rieckmann Grant Multiple Sclerosis Society Chair Endowment

500,000

New faculty start-up funds - MS Research Program


Neurology Ruth Grant CIHR Operating Grant MOP-67007 69,042

Development of Radiotracers Based on Oligonucleotide Labelling

Neurology Ruth Grant CIHR: Combined multi-user Equipment/ Maintenance PRG-81042

85,645

Maintenance for the UBC PET scanners

Neurology Ruth Grant CIHR Team Grant Program 286,247

CIHR Team in Parkinson's Disease-Core (C-Imaging Core)

Neurology Sossi Grant CIHR Operating Grant MOP-74638 294,993

In-vivo studies on disease and treatment-induced changes of levodopa-derived dopamine kinetics and DA transporter expression using a Parkinson's Disease rat model and a microPET

Neurology Spacey Grant National Ataxia Foundation 28,486

The role of P/Q type calcium channels in the pathogenesis and treatment of ataxia

Neurology Stoessl Grant Canada Research Chair Tier I (CIHR) 100,000

Canada Research Chair Tier I in Parkinson's Disease for Dr. Jon Stoessl

Neurology Stoessl Clinical Trial Kyowa Pharmaceutical Inc. 21,662

Protocol 6002-US-025: An Open-label, Multicentre Study of the Continued Safety of Istradefylline in Subjects with Parkinson's Disease who have Recently Completed One Year of Treatment with Istradefylline

Neurology Stoessl Grant Pacific Parkinson's Research Institute 100,000

James A. Moore Chair in Parkinson's research

Neurology Stoessl Clinical Trial Ceregene Inc. 192,984

PET Scanning in Association with a Phase I Open-label study of CERE-120 (Adeno-Associated Virus Serotype 2[AAV2]-Neurtuin [NTN]) to Assist the Safety and Tolerability of Intrastriatal Delivery to Subjects with Idiopathic Parkinson's Disease

Neurology Stoessl Grant CIHR Operating Grant MOP-15127 58,427

The natural history of sporadic and inherited Parkinson's Disease

Neurology Stoessl Grant MSFHR: Research Unit Infrastructure Support Program IN-RU-A-007(05-1)

200,000

MSFHR research unit in Parkinson's Disease and monoaminergic function in the central nervous system

Neurology Stoessl Grant Michael Smith Foundation for Health Research

1,042

The roles of expectation and dopamine in the placebo effect in Parkinson's Disease

Neurology Stoessl Clinical Trial Sanofi-Synthelabo Canada Inc. 24,486

Protocol ACT5288:Phase II Randomized Multicentre Multinational Double-Blind Placebo-Controlled Study of the Effect of SR57667B on Dopaminergic Nigro-Striatal Function Assessed by 18F-Dopa PET Imaging in Outpatients with Early Parkinson's...

Neurology Stoessl Clinical Trial Kyowa Pharmaceutical Inc. 17,399

6002-INT-001: A Long-term Multicenter Open-label Study with Oral 20 or 40 mg/doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complication on Levodopa Therapy


Neurology Stoessl Grant CIHR Operating Grant MOP-15126 148,157

Complications of Parkinson's Disease: The dopaminergic basis of depression

Neurology Stoessl Agreement National Parkinson Foundation (US) 76,140

National Parkinson Foundation, Centre of Excellence

Neurology Stoessl Grant Pacific Alzheimer Research Foundation

1,050,860

Overlap syndromes resulting in dementia

Neurology Stoessl Grant CIHR Team Grant CTP-79851 116,822

CIHR team in Parkinson's Disease: Core A - Clinical & Administrative Core


CIHR Team in Parkinson's Disease: Core B - Biostatistics & Mathematical modeling


CIHR Team Grant in Parkinson's Disease

Neurology Stoessl Grant MSFHR Senior Graduate Studentship Award ST-SGS-182(06-1)CLIN (Fellow: Lidstone, Sarah)

1,458

The effect of reward expectation and dopamine release on the mechanism of the placebo effect in Parkinson's Disease

Neurology Stoessl Contract Ceregene Inc. 80,799

PET Scanning in Assoc with a Multi-Center, Randomized, Double-Blind, Sham surgery controlled Study of CERE-120 (Adeno Associated Virus Serotype 2 {AAV2}-Neurturin {NTN} to Assess the Efficacy and Safety of Bilateral Intraputaminal (IPu) ...

Neurology Teal Clinical Trial Vernalis Ltd. 10

V10153-2S-01: A Phase II Multicenter Two-Part Study to Evaluate the Safety and Efficacy of V10153 in Acute Ischemic Stroke

Neurology Teal Clinical Trial National Institutes of Health 10,565

IICT : CREST - Carotid Revascularization Endarterectomy vs. Stenting Trial

Neurology Teal Clinical Trial Canadian Institutes of Health Research (CIHR)

1,350

FASTER: Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence Trial

Neurology Teal Clinical Trial Boehringer Ingelheim (Canada) Ltd. 40,482

9.159 PROFESS: Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind Active and Placebo Controlled Study of Aggrenox vs Clopidogrel and Aspirin with and without Micardis

Neurology Teal Agreement Servier Canada 49,645

CL3-18886-012 (The Perform Study) prevention of cerebrovascular and cardiovascular events of ischaemic origin with teRutroban in patients with a history of ischaemic stroke or transient ischaemic attack

Neurology Teal Clinical Trial NMT Medical Inc. 39,717

G980031 CLOSURE 1: Prospective Multicenter Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System vs Best Medical Therapy in Patients with a Stroke and/or Transient Ischemic Attack Due to Pre..

Neurology Teal Clinical Trial Forest Laboratories Inc. 3,000

PN01-01/CD 003 DIAS-2: Desmoteplase (INN) in Acute Ischemic Stroke Phase III


Neurology Teal Clinical Trial National Institutes of Health 21,578

IICT: Albumin in Acute Stroke (ALIAS) Trial

Neurology Teal Agreement Sanofi-Aventis Canada Inc. 5,460

CASTIA, PM-C-0225: Randomized, Double-Blind Study Comparing the Effect of a 3-Month Clopidogrel Regimen, Combined with ASA the First Month, Versus ASA Alone for the Acute Treatment of TIA/Minor Stroke Patients

Neurology Traboulsee Clinical Trial Centocor Inc. 1,551

C0743T06: A Phase II Double-Blind Placebo-Controlled Randomized Dose-Ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-Remitting Multiple Sclerosis

Neurology Traboulsee Clinical Trial Bayer Inc. (Canada). 6,500

Protocol 309363: International, Multicenter, Phase IIIb Study of Subcutaneous Every-Other-Day Treatment of Patients with Relapsing Multiple Sclerosis with (Phase A) Double-Blind Betaseron/Betaferon 250ug or 500 ug or ...

Neurology Traboulsee Clinical Trial Berlex Canada Inc. 81,861

306440 BEYOND Study: International Randomized Multicenter Phase 3b Study in Patients with Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of 104 Weeks: Double-Blinded SafetyTolerability and Efficacy of Betaseron/B..

Neurology Traboulsee Clinical Trial Transition Therapeutics and Diagnostics Inc.

44,586

IET-2O1: Open Label Baseline-to-Treatment Crossover Clinical Trial to Evaluate the Safety Tolerability Pharmacokinetics & Effects of Vitamin B12 When Used in Combination with Interferon-b Treatment in Patients with Relapsing Remitting MS...

Neurology Traboulsee Clinical Trial Genentech Inc. 59,694

U2786g: Phase II/III Randomized Double-Blind Parallel-Group Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rituximab in Adults with Primary-Progressive Multiple Sclerosis (PPMS)

Neurology Traboulsee Clinical Trial Aventis Pharma Inc. 29,509

Protocol HMR1726D/2002: Extension of Protocol HMR1726D/2002, A Phase II Study of the Safety & Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis with Relapses

Neurology Traboulsee Clinical Trial Sanofi-Aventis Canada Inc. 106,119

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Design Study to Evaluate the Efficacy and Safety of Teriflunomide (HMR1726D) in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability…

Neurology Traboulsee Clinical Trial ACORDA Therapeutics 10,799

MS-F204: Double-Blind, Placebo-Controlled, 13-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10mg b.i.d.) in Patients with Multiple Sclerosis


Neurology Traboulsee Clinical Trial Abbott Laboratories Ltd. (Canada) 3,543

M03-654: A 24-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding, Safety, Tolerability & Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects with Multiple Sclerosis with a 24-week Double-blind Active ...

Neurology Traboulsee Clinical Trial Sanofi-Aventis Canada Inc. 30,546

Long-term Extension of the Multinational, Double-blind, Placebo-controlled Study EFC6049 (HMR 1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 & 14mg) in Patients with Multiple Sclerosis with Relapses

Neurology Tremlett Grant National Multiple Sclerosis Society (US)

52,376

Do relapses effect disease progression? New perspectives on the natural history of MS from British Columbia

Neurology Tremlett Grant CIHR Operating Grant MOP-82738 38,389

The MaMS Study, Malignancy and Multiple Sclerosis: incidence and impact of beta-interferon treatment

Neurology Tremlett Grant Multiple Sclerosis Society of Canada 50,000

Don Paty Career Development Award

Neurology Tremlett Grant MSFHR Scholar Award CI-SCH-119(06-1)

33,750

The MaMs study. Malignancy and Multiple Sclerosis: incidence and impact of beta-interferon treatment

Neurology Tsui Clinical Trial Solstice Neuroscience Inc. 11,228

An Open Label Safety and Immunogenecity Study of MYOBLOC (NEUROBLOC; BOTULINIM TOXIN TYPE B) Injectable Solution in Patients with Cervical Dystonia

Neurology Tsui Clinical Trial Teva Neuroscience Inc. (Canada) 34,462

TVP-1012/500: A Multicenter, double-blind, randomized start, placebo-controlled, paralleled group study to assess Rasagiline as a disease modifying therapy in early Parkinson's disease subjects

Neurology Tsui Clinical Trial Eisai Medical Research Inc. 14,912

E2007-A001-302: A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations

Neurology Tsui Clinical Trial MERCK (Germany) 18,099

Protocol EMR 62 225-013 (SPIRID-O): An Open-Label Multicentre Multinational Follow-Up Study to Evaluate the Long-Term Safety & Maintenance of Efficacy of Sarizotan in Parkinson Patients with L-Dopa Induced Dyskinesia

Neurology Wang Grant (BRC) Canadian Institutes of Health Research (CIHR)

5,000

Research Allowance -- Animal modeling schizophrenia: A two-hit approach


40,000

Salary: Animal modeling schizophrenia: A two-hit approach

Neurology Wang Grant (BRC) Various Sources 180,659

Molecular mechanisms of AMPA receptor cycling

Neurology Wang Grant (BRC) Michael Smith Foundation for Health Research

25,000

Postsynaptic regulation of neurotransmission



171,021

Regulation of postsynaptic expression of GABA-A receptors

Neurology Wang Grant (BRC) NeuroScience Canada Foundation 110,000

Synaptic repair by peptides interfering with protein-protein interactions critical for synaptic plasticity and maturation: a rational pharmacology for restoring cognitive and emotional function


143,065

AMPA receptor regulation and synaptic plasticity

Neurology Wang Grant (BRC) Howard Hughes Medical Institute 113,705

Investigation into the molecular mechanisms underlying synaptic plasticity

Neurology Wang Grant (BRC) Michael Smith Foundation for Health Research

4,083

A subunit-specific role for NMDA receptor antagonism in neonatal seizures: in vivo and in vitro characterization

Neurology Wang Grant MSFHR Junior Graduate Studentship Award ST-JGS-045(05-1)BM (Fellow: Lai, Ted)

1,042

Activation of NR2A-containing NMDA receptor-mediated cell survival as a novel and innovative therapeutic strategy in the treatment of a stroke

Neurology Wang Grant Canadian Stroke Network (CSN) - Networks of Centres of Excellence (NCE) Graduate Studentship RFD1147 (Fellow: Lam, June)

5,000

CSN Summer Studentship - Neurodegeneration following stroke

Neurology Wang Grant CIHR Doctoral Research Award CGD-83640 (Fellow: Lai, Ted)

5,000

Activation of NR2A-containing NMDA receptor-mediated cell survival as a novel and innovative therapeutic strategy in the treatment of stroke

Neurology Wang Grant Heart & Stroke Fdn of British Columbia and Yukon Program/ Project Grant

120,740

Investigation into the molecular mechanisms mediating excitotoxicity - developing novel post-stroke therapies

Neurology Wang Grant HSFC/ CSN/ CIHR Doctoral Research Award (Fellow: Ge, Yuan)

857

Research Allowance: Modulation of AMPA receptor trafficking in the animal model of stroke

Neurology Wang Grant NCE/ Canadian Stroke Network (CSN) - Research

83,000

NMDA: Treatment of stroke with peptide and small molecule inhibitors of NMDA receptor-PSD95 interaction

Neurology Woolfenden Clinical Trial Novo-Nordisk 50,638

F7ICH-1641: Factor VII (Niastase) in Acute Intracerebral Hemorrhage

Neurology Woolfenden Grant National Institutes of Health 2,728

WASID

Neurology Woolfenden Clinical Trial National Institutes of Health 29,280

IICT: Interventional Management of Stroke Study III

Physical Medicine & Rehabilitation

Dhawan Agreement Victhom Human Bionics 20,951

VHB-3015-PR01-v00: Pilot Study of Neurostep System in Patients with Gait Disorder Secondary to Central Nervous System Lesion



Hughes Agreement Coloplast Corp. 34,632

DKO46CC: A Prospective, Randomized, Parallel-group, Multicenter Study to Investigate Urinary Tract Infections in Patients with Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters


Travlos Grant Allergan Inc. 10,000

Treatment of Thoracic Outlet Syndrome with Botulinum Toxin Injection: A Double-blind, Randomized, Controlled Trial


Van Rijn Grant Vancouver Coastal Health Authority

24,900

Salary: Research Nurse

Respiratory Medicine

Abboud Agreement Hoffmann-La Roche Ltd. (Canada) 45,000

PATIENT REIMBURSEMENT ACCOUNT FOR STUDY na17598


Abboud Agreement Hoffmann-La Roche Ltd. (Canada) 140,900

Protocol: NA17598D, A multicenter, double-blind, placebo-controlled randomized trial of the efficacy safety and tolerability of 12 months of once daily treatment with 5mg of RO3300074 in patients with symptomatic emphysema secondary to alphy…


Ayas Grant BC Lung Association: BC Lung/CIHR Investigator

6,250

Investigation of the diagnosis and treatment of sleep disordered breathing


Ayas Grant CIHR New Investigator 10,417

Investigation of the diagnosis and treatment of sleep disordered breathing


Ayas Grant MSFHR Scholar Award 65,417

The public health impact of obstructive sleep apnea hypopnea


Ayas Grant MSFHR HSPR Operating Grants Program - LOI

74,860

HSPRSN Investigative Teams development grant - Intensive Care Unit Patient Safety Team


Ayas Grant UBC Department of Medicine 25,000

The Public Health Impact of Obstructive Sleep Apnea Hypopnea (OSAH)


Bai Grant British Columbia Lung Association 30,000

Airway structural phenotypes in asthma


Bai Grant CIHR: Request for Proposal/Application

114,717

Environmental impact on the epithelial immune barrier in asthma


Bai Grant Astra Charnwood 98,489

Asthma Research Clinic


Bai Grant Allergy, Genes and Environment Network (AllerGen) - Networks of Centres of Excellence

55,000

Environmental impact on the epithelial immune barrier in asthma


Bai Clinical Trial Boehringer Ingelheim (Canada) Ltd. 12,375

Protocol 1222.6 (Project Nickname BI 1744 CL): A randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy (Bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2up, 5up)



Bai Clinical Trial Intermune Pharmaceuticals Inc. 890

A randomized, double-blind, placebo-controlled phase II study of the safety and efficacy of subcutaneous recombinant interferon-y1b (rlFN-y 1b) in patients with idiopathic pulmonary fibrosis


Bai Clinical Trial Topigen Pharmaceuticals Inc. 11,112

Protocol Topigen Asthma Study: A phase II, , randomised, double-blind, placebo-controlled, parallel-groups, multicentre study to evaluate and compare the safety, tolerability, and efficacy of two dosages of inhaled TPI ASMB (0.25 mg and 0.5 mg)


Carlsten Grant Vancouver Coastal Health Authority 75,000

Particle exposure health effects research facility


Carlsten Grant UBC Department of Medicine 20,000

Start-Up Funds from Respiratory Division


Cook Grant MSFHR: Institutional Infrastructure Support Program

100,000

In it for Life Mentored Clinician Scientist Award: Using location-based screening to improve tuberculosis control efforts in high-risk communities of the Vancouver Coastal Health Authority


Duronio Grant CIHR: Operating Grant MOP-74481 141,673

Mcl-1 as a regulator of cell cycle progression


Duronio Grant Heart and Stroke Foundation of British Columbia and Yukon - Research

70,482

Activation of macrophage growth and survival pathways by oxidized LDL


Duronio Grant CIHR/Strategic: Request for Applications (Full) MIF-79630

154,258

The mechanistic basis of post-lung transplantation bronchiolitis obliterans and therapeutic approaches


Duronio Grant MSFHR: Postdoctoral Trainee Fellowship ST-PDF 164(03-1)BM (Fellow: Germain, Marc)

9,750

Analysis of nuclear and cytoplasmic Mcl-1 protein complexes


Duronio Grant CIHR: Postdoctoral Fellowship MFE-78141 (Fellow; Scott, Alexander)

5,000

Research allowance: Characterizing apoptosis and survival pathways in tendon: the pathogenesis of overuse tendinopathy and its treatment with IGF-1


Duronio Grant CIHR: Postdoctoral Fellowship MFE-78141 (Fellow; Scott, Alexander)

50,000

Salary: Characterizing apoptosis and survival pathways in tendon: The pathogenesis of overuse tendinopathy and its treatment with IGF-I


Duronio Grant Canadian Cystic Fibrosis Foundation - Research Grants

5,000

The mechanistic basis of post-lung transplantation bronchiolitis obliterans and therapeutic approaches


Fitzgerald Grant AstraZeneca Canada Inc. 20,000

Asthma and Health Literacy in New Immigrant Communities in the Greater Vancouver Area (GVA): A Preliminary Proposal


Fitzgerald Agreement GlaxoSmithKline (Canada) Inc. 110,481

ECLIPSE: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These with Forced Expiratory Volume in 1 Second (FEV) for their ability to Measure and Predict COPD Severity and its progression Over Tim



Fitzgerald Agreement GlaxoSmithKline (Canada) Inc. - Asthma PRIISME Program

100,000

The Development of Asthma Education Programs Through a Novel Chronic Disease Management Model: PRIISM


Fitzgerald Agreement Novartis Pharmaceuticals Canada Inc.

3,000

CQAB149B2335S: A 26 Week Treatment, Multicenter, Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (selected fro,


Fitzgerald Agreement Boehringer Ingelheim (Canada) Ltd. 9,750

BI1744CL - 1222.6: Randomized, Double-Blind, Placebo-Controlled, Parallel Group study to Assess the Efficacy (Bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2ug, 5ug, 10ug, 20ug) delivered by Ri


Fitzgerald Agreement Topigen Pharmaceuticals Inc. 17,254

TPI ASM8-204: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, Multicenter Study to Evaluate and Compare the Safety, Tolerability and the Efficacy of Two Dosages of Inhaled TPIASM8 (0.25mg vs 0.5mg) with Placebo i


Fitzgerald Grant MSFHR: Scholar Award 103,013

Bringing evidence to the patient


Fitzgerald Grant CIHR: Doctoral Research Awards CGD-80423 (Fellow: Moniruzzaman, A.K.M.

5,000

Research Allowance: Treatment of latent TP infection: measuring effectiveness among the contacts of TB cases


Fitzgerald Clinical Trial National Cancer Institute of Canada - Clinical Trials Group

6,000

IICT: A Phase III Randomized Study of Exemestane vs. Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer


Fitzgerald Contract US Centers for Disease Control and Prevention

45,449

Task 13: Factors associated with acceptance of adherence to toxicity from treatment for Latent Tuberculosis Infection (TLTBI) and pilot study of TLBI effectiveness


Fitzgerald Clinical Trial CIHR: Randomized Controlled Trials 13,400

IICT: Asthma in Obese Subjects - Diagnostic & Therapeutic Strategies


Fitzgerald Agreement Hoffmann-La Roche Ltd. (Canada) 6,000

NA20030A: Roche Integrin Antagonist Follow-up for Undetected PML


Fitzgerald Clinical Trial GlaxoSmithKline (Canada) Inc. 13,552

SCO100250: A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/..


Fitzgerald Grant CIHR Team Grant Program - Letter of Intent

10,000

CIHR Team in Respiratory Clinical Research


Fitzgerald Agreement Wyeth Canada 28,507

Protocol 3174K1-200-Ca: The Effects of IMA-638 on Allergen-Induced Airway Responses and Airway Inflammation in Subjects with Mild Atopic Asthma




625

CIGE025ACA02: XCEED Xolair Canadian Evaluation of Effectiveness in Asthmatic Disease: A Post-registration Evaluation of Long Term Xolair (omalizumab) Therapy on Patient-relevant Outcomes, Medical Resource Use and Asthma Medication Requirements


Fitzgerald Agreement Skye Pharma 27,294

SKY2028-3-002 A Double-blind, Active-controlled, Parallel-group, Stratified, Multicenter, 12-week Study Comparing The Safety and Efficacy of Fluticasone and Formoterol combination (Flutiform 100/10ug twice daily) in a Single Inhaler - SkyePhn


Fitzgerald Agreement Genentech Inc. 5,808

Q4160g A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Lyphilized and Aged Liquid Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults…


Fitzgerald Grant CIHR/BC Lung Assn: Investigator 10,238

Bringing evidence to the patient



4,000

CIGE025A2433: International Registry of Real-World Outcomes for Asthma Patients Treated with Xolair


Fleetham Grant CIHR/ Canadian Lung Association Postdoctoral Fellowship BCF-82235 (Fellow: Mulgrew, Alan)

2,500

Research Allowance: The inflammatory and Cardiovascular Phenotype of Obstructive Sleep Apnea Hypopnea Syndrome


Fleetham Grant MSFHR: Research Unit Infrastructure Support Program

139,000

Respiratory Sleep Disorders Research Unit


Fleetham Grant VCHA: Venture Grants 30,000

Dynamic 3-Dimensional Upper Airway Modeling of the Effect of Oral Appliances for the Treatment Obstructive Sleep Apnea/Hypopnea


Fleetham Grant CIHR/ Canadian Lung Association Postdoctoral Fellowship BCF-82235 (Fellow: Mulgrew, Alan)

25,000

Stipend: The inflammatory and Cardiovascular Phenotype of Obstructive Sleep Apnea Hypopnea Syndrome


Fleetham Grant British Columbia Lung Association Fellowship (Fellow: Mulgrew, Alan)

27,500

The inflammatory and Cardiovascular Phenotype of Obstructive Sleep Apnea Hypopnea Syndrome


Khalil Grant British Columbia Lung Association 22,500

Alveolar Epithelial Cell Derived TGF-B1 Regulation of Fibroblast Function


Khalil Contract Pacific Therapeutics Ltd. 145,000

CRA: Therapeutic Applications of CD36 9-110 Peptide in Progressive and Lethal Diseases


Khalil Agreement InterMune Inc. 34,795

PIPF-004: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis


Knight Grant CIHR Operating Grant 82,152

Regulation of gp130 signaling by STAT-3 in the pathogenesis of pulmonary fibrosis



Knight Grant Canada Fdn for Innovation - Cdn matching funds

15,075

Mechanisms of airway disease


Knight Grant Canada Fdn for Innovation - US matching funds

6,982

Mechanisms of airway disease


Knight Agreement UBC Industry Liaison Office 10,000

Novel Method for Treatment of Asthma


Knight Grant Sepracor Inc. 45,000

The role of epithelial stem/progenitor cells in epithelial repair


Knight Clinical Trial Sepracor Inc. 24,005

The role of (R) and (S) enantomers of albuterol in mucosal injury and repair in pediatric asthma


Lam Clinical Trial Asthmatx Inc 10,867

Feasibility Study of the Broncus Alair System for the treatment of asthma


Levy Clinical Trial Actelion Pharmaceuticals Canada Inc.

1,110

A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy, safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis


Levy Clinical Trial GlaxoSmithKline (Canada) Inc. 62,835

A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These with Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and its Progression Over SCO104960


Levy Grant Universite Laval 16,193

IC077202 Effects of home-based versus hospital-based outpatient pulmonary rehabilitation ion patients with COPD: A multicenter, randomize clinical trial


Levy Clinical Trial Encysive L.P. 10,175

Protocol FPH03 STRIDE III: Long-Term Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension


Levy Agreement GlaxoSmithKline (Canada) Inc. 120,000

ECLIPSE: A multicentre, 3-year study to compare novel COPD biomarker endpoints with FEV1 in patients with COPD and control subjects


Man Grant CIHR - Rx & D: Research Program COP-76849

51,700

Systemic biomarkers in COPD: Can they predict future cardiovascular and cancer morbidity in COPD?


McWilliams Grant VCHRI 20,000

Equipment Fund


McWilliams Grant Vancouver Coastal Health Authority 50,000

MCS: Comparison of EBUS-TBNA and Surgical Lymph Node Sampling: A Feasibility Study


McWilliams Grant VGH and UBC Hospital Foundation 80,000

Equipment fund


McWilliams Grant UBC Faculty of Medicine 20,000

Start-up funds: MCS: Comparison of EBUS-TBNA and Surgical Lymph Node Sampling: A Feasibility Study



Ostrow Clinical Trial Lilly ICOS 28,772

Protocols LVGX and LVGY: A Randomized Double-Blind, Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension


Ostrow Agreement United Therapeutics Corp. 16,762

TDE-PH-301: A 16 week, International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR Tablets in Combination with an Ednothelin Receptor antagonist and/or a Phosphodiestera


Ostrow Agreement United Therapeutics Corp. 82

TDE-PH-304: An Open-Label Extension Trial of UT015C in Subjects with Pulmonary Arterial Hypertension


Pare Contract National Institutes of Health 1,255

Smoke Induced Airway Injury in COPD


Pare Grant CIHR Research Development Grant 13,377

The use of high resolution computed tomographic scanning in the phenotyping of COPD. Validation and application in a clinical trial


Pare Grant MSFHR Research Unit Infrastructure Support Program

246,125

Genetic-environment interactions lead to the phenotypic expression of inflammatory heart, lung and blood vessel diseases


Pare Grant CIHR Operating Grant 110,850

Genetics and Epigenetic Determinants of Asthmatic Epithelia Cell Phenotype


Pare Grant Merck Frosst Canada Ltd. 84,115

GEODE/ Alveolar Macrophage Gene Expression in COPD; Gene Expression in Obstructive Lung Disease and Emphysema (GEODE)


Pare Grant CIHR Operating Grant 121,360

Human airway smooth muscle function and bronchial hyper responsiveness: Length adaptation in airway smooth muscle


Pare Grant MSFHR Senior Graduate Studentship Award

2,500

Genetic and epigenetic studies of innate immunity related genes in the development of asthma in childhood: the role of airway epithelial cells


Pare Grant British Columbia Lung Association - Investigator

32,500

BC Lung Association/St. Paul's Hospital Investigator Award: Dr. Don Sin


Pare Grant Heart and Stroke Foundation of Canada - Strategic Training Initiatives

34,065

IMPACT: Integrated and mentored pulmonary and cardiovascular training


Pare Grant Canadian Institutes of Health Research (CIHR): Postdoctoral Fellowship (Fellow: Daley, Denise)

5,000

Investigation of epistasis and genetic susceptibility to hypertension in men and women


Pare Grant CIHR: Strategic Training Program Grant - Institute of Aging

273,413

IMPACT: Integrated and mentored pulmonary and cardiovascular training


Pare Grant CIHR: Physical Medicine Research Foundation/CIHR Fellowship (Fellow: Camp, Patricia)

5,000

Gender differences in chronic obstructive pulmonary disease



Pare Grant Canadian Institutes of Health Research (CIHR): Postdoctoral Fellowship (Fellow: Daley, Denise)

40,000

Investigation of epistasis and genetic susceptibility to hypertension in men and women


Pare Clinical Trial GlaxoSmithKline (Canada) Inc. 34,094

CRA: Develop and standardize accurate measurements of emphysema and airway wall dimensions in human lungs


Road Agreement Synapse Biomedical Inc. 2,978

Electrical Activation of the Diaphragm for Ventilatory Assist (Multi-Center Pivotal Study of NeuRx RA/4 Ventilatory Assist Device)


Road Agreement AstraZeneca AB 10,255

D5892C00015: A 12 week, double-blind, randomised, parallel group, multi-centre, study to evaluate efficacy and safety of budesonide/formoterol (Symbicort Turbuhaler) 320/9 ug one inhalation twice daily on top of tiotropium (Spiriva) 18ug on


Road Clinical Trial Spiration Inc. 115,981

CPR-0003: Study to Find Out If a New Medical Device Called the Intra-Bronchial Valve (IBV) is Safe and Effective to Use in Subjects With Severe Emphysema


Road Grant Rick Hansen Man In Motion Foundation

4,480

Electrical Activation of the Diaphragm for Ventilatory Assist Clinical Study


Road Agreement Nycomed Canada Inc. 39,598

BY217/M2-127 "THE EOS STUDY" -- Effect of Roflumilast in COPD Patients treated with Salmeterol: A 24-week, Double-blind Study with 500 ug Roflumilast Once Daily vs. Placebo


Sandford Grant Canadian Cystic Fibrosis Foundation - Research Grants

94,530

Genetic modifiers of disease severity in cystic fibrosis


Sandford Grant Canadian Lung Association - CLA/MRC Fellowship

45,000

Genetic polymorphisms in costimulatory molecules and the development of asthma


Sandford Grant Canada Research Chair Tier II (CIHR)

100,000

Canada Research Chair in genetics of respiratory disease for Dr. Andrew Sandford


Sandford Grant MSFHR Scholar Award 80,000

Genetic modifiers of pulmonary disease severity in cystic fibrosis


Sin Grant MSFHR Establishment Grant 37,500

Why are women at increased risk of chronic obstructive pulmonary disease and lung cancer? Is inflammation the missing link?


Sin Grant AstraZeneca Canada Inc. 108,075

Molecular Links Between Lung and Systemic Inflammation in COPD


Sin Grant CIHR: University-Industry Program - Operating Grants

96,228

Longitudinal Study of Disease Progression in COPD


Sin Grant Merck Frosst Canada Ltd. 35,000

Biomarker


Sin Grant Canadian Institutes of Health Research (CIHR)

111,553

Why are women at increased risk of chronic obstructive pulmonary disease and lung cancer? is inflammation the missing link?



Sin Grant MSFHR: Team Start-up Infrastructure Award

75,000

COPD and inflammation team (CAIT)


Sin Grant Canadian Lung Association: Scholarships in Respiratory Health Type I and II

7,500

A pilot study of barriers participating pulmonary rehabilitation programs


Sin Grant CIHR/IMHA Interdisciplinary Capacity Enhancement (ICE) Team

288,126

Interdisciplinary Capacity Enhancement: Bridging Excellence in Respiratory Disease and Gender Studies (ICEBERGS)


Sin Clinical Trial GlaxoSmithKline (Canada) Inc. 5,353

Protocol AIM (ADC105931): A Randomized, Double-Blind, Parallel-Group, 14-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/ Salmeterol DISKUS 250/50mcg BID Compared to Salmeterol DISKUS 50mcg BID in Subjects With…


Sin Grant CIHR Team Grant Program - Letter of Intent

10,000

Chronic Obstructive Pulmonary Disease (COPD): From Molecules to Population


Sin Grant MSFHR: Matching Establishment Grant

75,000

Why are women at increased risk of chronic obtrusive pulmonary disease and lung cancer? Is inflammation the missing link?


Sin Grant CIHR: TUTOR-PHC Fellowship (Fellow: Guo, Su-Er)

5,000

A pilot study of barriers to participating pulmonary rehabilitation programs


Sin Clinical Trial AstraZeneca AB 4,000

Protocol D5892C00015 (CLIMB): A 12-WEEK, DOUBLE-BLIND, RANDOMISED, PARALLEL GROUP, MULTI-CENTRE STUDY TO EVALUATE EFFICACY AND SAFETY OF BUDESONIDE/ FORMOTEROL (SYMBICORT(R) TURBUHALER(R)) 320/9 ug ONE INHALATION TWICE DAILY ON TOP OF TIOT


Sin Grant MSFHR Senior Scholar Award 15,000

Why are women at increased risk of chronic obstructive pulmonary disease and lung cancer? Is inflammation the missing link?


Sin Grant Canada Research Chair Tier II (CIHR)

100,000

Canada Research Chair in Chronic Obstructive Pulmonary Disease for Dr. Don Sin


Sin Clinical Trial St. Joseph's Health System 155,205

IICT: Can Advair and Flovent reduce systemic inflammation related to COPD? A multi-center randomized controlled Trial.


Swiston Grant UBC Department of Medicine 20,000

Risk factors for hospital readmission in patients with COPD


Swiston Grant VCHRI: In it for Life Investigator Awards

50,000

Risk factors for hospital readmission in patients with COPD


Tebbutt Grant Allergy, Genes and Environment Network (AllerGen) - Networks of Centres of Excellence

36,000

AllerGen Animations


Tebbutt Grant National Sanitarium Association 80,000

Real-Time Clinical Genomics In Pulmonary Medicine



61,940

Knowledge, discovery, management and transfer - AllerGen Theme I Web Resource



55,020

Mini-CHILD Genetics



70,000

Development of a Microarray Genotyping Chip for Clinical Trials


Van Eeden Clinical Trial National Institutes of Health 59,420

IICT: Diesel Exhaust and Atherosclerotic Plaque Stability


Van Eeden Grant MSFHR: Senior Graduate Studentship Award

4,417

Particular matter air pollution induces vascular endothelial dysfunction


Van Eeden Agreement GlaxoSmithKline (Canada) Inc. 50,000

PRIISME PROGRAM


Van Eeden Grant British Columbia Lung Association 20,000

Particulate Matter Air Pollutants and Chronic Obstructive Pulmonary Disease


Van Eeden Grant MSFHR: Senior Scholar Award CI-SSH-080(05-1) CLIN

100,000

Lung inflammation induced cardiovascular disease


Ward Grant Agriculture Canada 2,000

Canadian Agricultural Injury Surveillance Program


Wilcox Clinical Trial InterMune Inc. 48,840

A Randomized, Double-blind, Placebo-controlled, Phase III Three-arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis


Wilcox Grant Ottawa Health Research Institute 1,860

IICT: Evaluation of a Decision Aid for Adult Cystic Fibrosis patients Considering Bilateral Lung Transplantation


Wilcox Clinical Trial Intermune Pharmaceuticals Inc. 20,616

A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of Interferon Gamma-1b in patients with idiopathic pulmonary fibrosis -- the INSPIRE Trial: INternational study of Survival outcomes in IPF with InteRfEron


Wilcox Clinical Trial Boehringer Ingelheim (Canada) Ltd. 28,172

205.372-Spiriva Respimat(TM) Study: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one-year) Efficacy and Safety of Tiotropium Inhalation Solution 5ug (2 puffs of 2.5ug) Delivered by the Respimat


Wilcox Clinical Trial Perceptronix Medical Inc. 3,000

Protocol FLUTE: Evaluation of "Lung Flute" TM for Sputum Collection


Wilcox Clinical Trial Pharmaxis Ltd. 3,576

DPM-CF-202: A Phase IIA, Randomised, Open-label, Dose-response Study to Determine the Optimum Dose of Dry Powder Mannitol Required to Generate Clinical Improvement in Patients with Cystic Fibrosis


Wilcox Clinical Trial Perceptronix Medical Inc. 20,206

Spectral Imaging of Early Lung Cancers and Pre-Cancerous Lesions


Wilcox Clinical Trial Corus Pharma Inc. 7,750

A Phase 3, Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with P. Aeruginosa (AIR-CF1)


Wilcox Clinical Trial Actelion Pharmaceuticals Canada Inc.

28,010

Protocol AC-052-321 BUILD 3: Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Event-Driven, Group Sequential, Phase

Rheumatology Choi Grant Canadian Institutes of Health

Research (CIHR)

32,894 Role of statins in prevention and management of rheumatoid arthritis

Rheumatology Cibere Grant CIHR Clinician Scientist - Phase II MC2-69188

62,488

Development of a Model for the MRI Progression of Knee Osteoarthritis

Rheumatology Esdaile Grant CIHR: Request for Proposal/Application

150,000

Tooling Up for OA: Measuring What Matters

Rheumatology Esdaile Grant Canadian Arthritis Network (CAN) - Networks of Centres of Excellence (NCE)

150,000

Tooling Up for OA: Measuring What Matters

Rheumatology Esdaile Grant CIHR / Rx&D Research Program - Postdoctoral Fellowship XWY-82340 Fellow: Avina-Zubieta, Juan Antonio)

10,000

Research Allowance: Cardiovascular morbidity and mortality associated with the use of corticosteroids in patients with rheumatoid arthritis. A population based study

Rheumatology Lacaille Grant Arthritis Society Investigator Award 80,500

Evaluating care for rheumatoid arthritis and preventing work disability in inflammatory arthritis

Rheumatology Lacaille Grant Disabilities Health Research Network (DHRN)

7,923

Carrier Sekani First Nations Band Telerehabilitation Project - Research Planning Workshop

TOTAL:

40,723,460

division researcher type sponsor 2007 title ......samples from clinical trial protocols a4001027,...

Documents